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1. ABBREVIATIONS 
 
BiFC Bimolecular fluorescence complementation 
BSA Bovine serum albumin 
CD Circular dichroism 
cELISA Cellular enzyme linked immunosorbent assay 
CHO Chinese hamster ovary 
CNS Central nervous system 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's modified Eagle medium 
DTE Dithioerythritol 
EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein  
ERK2 Extracellular signal-regulated kinase 2 
ELISA Enzyme linked immunosorbent assay 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
FL Full length 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
IDP Intrinsically disordered protein 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
LB Luria-Bertani medium 
MAP Microtubule associated protein 
ME 2-mercaptoethanol 
MES 2-(N-morpholino)ethanesulfonic acid 
MSA Multiple system atrophy 
MT  Microtubule 
MTOC Microtubule organizing center 
NMP Neomorphic moonlighting protein 
NMR Nuclear magnetic resonance 
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NMWL Nominal molecular weight limit 
OLG Oligodendrocyte 
PBS Phosphate buffered saline 
PD Parkinson’s disease 
PMSF Phenylmethylsulfonyl fluoride 
RT Room temperature 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SYN -synuclein 
TPPP/p25 Tubulin Polymerization Promoting Protein/p25 
Tris Tris(hydroxymethyl)aminomethane 
C TPPP/p25 C-truncated TPPP/p25 (175-219) 
N TPPP/p25 N-truncated TPPP/p25 (3-43) 
CORE TPPP/p25 Terminally double truncated TPPP/p25 (3-43/175-219) 
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2. INTRODUCTION   
 
Moonlighting proteins comprise proteins with multiple, independent functions that do not 
originated from alterations of the genetic code, splice variants or post-translational modifications 
(Jeffery 1999). There are multifunctional proteins which physiological functions can be switched, 
converted into a pathological one, described as neomorphic moonlighting proteins (NMP, Jeffery 
2011). Their interactions with distinct protein partners could lead to the formation of protein 
aggregates that form brain inclusions. Such destructive potential is characteristic for the 
intrinsically unstructured proteins (IDP) which do not have well-defined three-dimensional 
structure, yet fulfill essential functions linked to their structural states; however, their 
macromolecular assemblies frequently result in pathological inclusions (Uversky 2014). Tubulin 
Polymerization Promoting Protein/p25 (TPPP/p25) (Hlavanda et al. 2002) is a prototype of the 
NMPs (Ovádi 2011, Oláh et al. 2013): physiologically it modulates the dynamics and stability of 
the microtubule (MT) network via its tubulin polymerization and acetylation promoting, MT 
bundling activities (Hlavanda et al. 2002, Tirián et al. 2003, Tőkési et al. 2010); but it also plays a 
role in different neurological disorders due to its interactions with -synuclein (SYN) and -
amyloid, which promote aggregation (Kovács et al. 2004, Oláh et al. 2011).  
TPPP/p25 is an IDP, its extended unstructured N- and C-termini are straddling a flexible 
core region (Orosz et al. 2004, Zotter et al. 2011a). Among the binding segments, the guanosine 
triphosphate (GTP, Zotter et al. 2011a) and Zn2+ (Zotter et al. 2011b) are well characterized, while 
the tubulin binding motif was predicted based upon its homology with the tubulin binding motif 
of tau protein (Hlavanda et al. 2007). It has been shown that Zn2+ binds to a specified segment of 
the middle, flexible region of TPPP/p25 resulting in alteration in the secondary but not in the 
tertiary structure (Zotter et al. 2011b); however, the physiological relevance of the binding was 
not investigated in detail. 
In normal brain, TPPP/p25 is predominantly expressed in oligodendroglial cells 
(Takahashi et al. 1993, Skjoerringe et al. 2006); where it is indispensable for the differentiation of 
the progenitor cells by its role in the rearrangement of the MT network in the course of the 
projection elongation necessary to axon ensheathment (Lehotzky et al. 2010). The non-
physiological TPPP/p25 expression can generate distinct central nervous system (CNS) diseases: 
i) the loss of TPPP/p25-positive oligodendrocytes (OLGs) in demyelinated lesions with a 
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concomitant enrichment of TPPP/p25 in the cerebrospinal fluid of patients is characteristic for 
multiple sclerosis (Höftberger et al. 2010, Vincze et al. 2011); ii)  the lack of TPPP/p25 expression 
in OLGs is typical in glioma (Preusser et al. 2007); iii) the abnormal co-enrichment of TPPP/p25 
with SYN in the inclusion bodies of OLGs and in neurons is representative for multiple system 
atrophy (MSA) and Parkinson’s disease (PD) (Kovács et al. 2004), respectively, highlighting 
TPPP/p25 as a powerful diagnostic marker and a potential drug target. 
SYN, also a disordered NMP (Uversky 2003), is an extensively studied hallmark protein 
of synucleinopathies, such as dementia with Lewy bodies, PD and MSA; it is the major component 
of inclusion bodies in these diseases (Stephanis 2012, Vieira et al. 2015, Kim et al. 2014). SYN is 
a neuronal protein that under physiological conditions is localized preferentially to presynaptic 
terminals (Iwai et al. 1995, Murphy et al. 2000), but its exact function is still unclear. Recently it 
has been reported that its small, soluble oligomeric forms are the fatal species in the development 
of diseases (Dehay et al. 2015, Roberts et al. 2015, Winner et al. 2011). Nevertheless, no effective 
and specific drug has been developed for the therapeutic treatment of PD and other 
synucleinopathies. 
The major objective of my PhD thesis was to characterize the interactions of the 
disordered TPPP/p25 with its physiological partners such as tubulin/MT and the bivalent Zn2+ 
cation as well as with its pathological partner, SYN; and to establish the functional consequences 
of these interactions at molecular and cellular levels. In addition, I aimed to search for a potential 
drug target in order to specifically destruct the pathological assembly of TPPP/p25 and SYN.  
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3. SCIENTIFIC BACKGROUND 
 
3.1. The cytoskeleton of eukaryotes 
 
The cytoskeletal network of most eukaryotic cells comprises three different types of 
complex ultrastructural filamentous networks: actin filaments, intermediate filaments and the MT 
network, which display multifarious functions. In the course of growth, proliferation or 
differentiation the cytoskeletal network has to be rearranged derived by its highly dynamic 
structure undergoing constant and rapid reorganization (Alberts 2014 and references therein). In 
an animal cell, actin filaments are found in the cell cortex, which is the meshwork of membrane-
associated proteins that supports and strengthens the plasma membrane, providing strength and 
shape necessary for the locomotion of the cell. It also allows cells to hold certain shapes, such as 
microvilli, lamellipodia and filopodia; as well as it is involved in contractile ring formation, which 
creates the cleavage furrow during mitosis. Intermediate filaments are made of a large and 
heterogeneous group of subunits, which form generally strong ropelike structures, providing 
mechanical support. Some cells have multiple types of intermediate filaments and some are 
associated with specific cell types. For example, keratins are found specifically in epithelial cells, 
neurofilaments help to extend the long axons in neurons; while lamins are found in all cell types, 
providing structural reinforcement to the cell nucleus. The MT system provides platforms for 
intracellular transport, including the movement of motor proteins with macromolecular 
assemblies, vesicles and also organelles; it forms the mitotic spindle, which helps the 
rearrangement of the dividing cell; and it is also the main constituent of the organelles cilia and 
flagella responsible for cellular movement (Alberts 2014). 
 
3.1.1. The microtubule network 
 
Microtubules are polymers of two closely related globular proteins, - and -tubulin, 
which associate spontaneously into a functional subunit. Tubulin polymers assemble into 
protofilaments and 13 protofilaments form the MT. It is the largest type of filaments with a 
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diameter of about 25 nm. The MT is a hollow structure; its inner diameter is about 12 nm. In 
eukaryotic cells, the polymerization of tubulin dimers typically starts in the microtubule-
organizing center (MTOC) in the centrosome, attached to a -tubulin ring complex. The tubulin 
dimer assembles into MT with its -tubulin part to the  part of another tubulin already 
incorporated into the MT, thus the polymerization is a polar process, which reflects not only the 
polarity of the tubulin dimer, but dictates the polarity of the MT as well (Howard et al. 2003). The 
end of the MT attached to the centrosome is called the minus end, while the other, where both the 
growth and the shrinkage are fast, is called the plus end (Alberts 2014). Both - and -tubulin bind 
GTP, but it is only exchangeable in -tubulin, which possesses a GTPase activity by hydrolyzing 
it to guanosine diphosphate (GDP). The presence of GTP or GDP on β-tubulin influences the 
stability of the dimer in the MT: if β-tubulin is bound to GTP, the tubulin dimer tends to assemble 
into MTs, while if β-tubulin is bound to GDP, the microtubule tends to fall apart, since the GTP 
hydrolysis weakens the binding affinity of tubulin for adjacent tubulin dimers. Therefore, GTP 
hydrolysis is a main factor in the dynamic instability of the MTs. As long as GTP-bound tubulin 
dimers are added more rapidly than GTP is hydrolyzed, a cap of GTP-bound tubulin exists at the 
plus end, protecting the growing MT from disassembly. Without the sufficient rate of 
incorporation, the GDP-bound tubulin rapidly depolymerizes, thus the MT occasionally switches 
to rapid shrinkage, which is called MT catastrophe, then dynamically it can be rescued by 
switching back from shrinkage to growth. MT catastrophe is a major mechanism for MT length 
regulation (Gardner et al. 2013). 
 
3.1.2. Microtubule associated proteins 
 
There are a number of protein families which regulate the stability of the MT. Microtubule 
associated proteins (MAPs) were originally identified as proteins co-purified with MTs during 
repeated cycles of MT assembly and disassembly, meaning the tightly associated (static) MAPs 
only (Olmsted 1986); however, this definition has been broadened to involve the dynamically 
associated proteins as well (Mandelkow et al. 1995). MAP activity is controlled by kinases and 
phosphatases (Cassimeris et al. 2001). Well known proteins belong to static MAPs: MAPla and 
lb, MAP2a, 2b, and 2c, MAP4, tau protein, 205 kDa MAP, and the isoforms of these proteins that 
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are often generated by alternative splicing (Mandelkow et al. 1995). These structural MAPs 
stabilize and promote the assembly of MTs in various ways, they attach to each other to form 
scaffolds or bundles the MTs (Alberts 2014), these MAPs organize the individual filaments into 
long lived and well organized tracks (Richter-Landsberg 2008) and protect the MT against 
disassembly (Denarier et al. 1998). The MAP2/Tau family possesses repeated tubulin binding 
domains, which allows them to associate with more than one heterodimer, holding the 
protofilaments together (Dehmelt et al. 2005). Another protein family, the stable tubule only 
(STOP) proteins may contribute to the cold and drug stability of MTs (Slaughter et al. 2003). 
Not all MAPs stabilize the MT: catastrophe factors destabilize the tubulin polymer by 
increasing the frequency of catastrophes such as Kip3 (Varga et al. 2009) and MCAK (Ritter et al. 
2015) or inhibiting nucleation (Wieczorek et al. 2015). Microtubule-severing enzymes are also 
important MT regulators (Sharp et al. 2012). Katanin is capable of disrupting contacts between α- 
β-tubulins in the wall of MTs (Zhang et al. 2007). Spastin (Roll-Mecak et al. 2008) and fidgetin 
(Mukherjee et al. 2012) could release MT minus ends from centrosomes; spastin forms a 
hexameric ring and pulls the C-terminus of tubulin through its central pore, therefore destabilizes 
the MT lattice (Roll-Mecak et al. 2008). The regulation of the MT network is a complex process 
due to the interplay of many proteins, which function by a variety of mechanisms.  
Other proteins often found to be associated and even co-purified with MTs, although they 
are usually not considered as MAPs (Mandelkow et al. 1995), e.g. kinases (protein kinase A, GSK-
3 and c-mos), MT motor proteins (kinesin, dynein), proteins involved in biosynthesis (elongation 
factor EF-la, purinosome complex) (Durso et al. 1994, An et al. 2010) and glycolytic enzymes 
(glyceraldehyde-3-phosphate dehydrogenase, aldolase, phosphofructokinase) (Knull et al. 1992, 
Lehotzky et al. 1993,Vértessy et al. 1997).  
 
3.2. The Tubulin Polymerization Promoting Protein/p25  
 
A protein with random coil structure was isolated from bovine brain by the research group 
of Prof. Judit Ovádi and was denoted Tubulin Polymerization Promoting Protein (TPPP/25) on the 
basis of its molecular mass and in vitro function: it polymerizes tubulin into intact and aberrant 
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MTs and also bundles them as shown by electron microscopic images (Fig. 1, Hlavanda et al. 2002 
and 2007). 
 
 
Fig. 1. Transmission electron microscopy images of the TPPP/p25-induced tubulin assemblies (A, B). A 
and B, bundles of MTs sectioned at different angles and thread-like oligomers aggregated into dense 
knobs are shown. The MTs are frequently covered by tiny projections and periodically arranged dense 
particles (B), which form cross-links between MTs (see inset in panel B).  Bars, 200 nm in A, 100 nm 
in B and 50 nm in the inset. (Hlavanda et al. 2007) 
 
3.2.1. The disordered nature of TPPP/p25 
 
There are several algorithms (PONDR: Romero et al. 1997; IUPred: Dosztányi et al. 
2005; FoldIndex: Prilusky et al. 2005, Uversky et al. 2000) which predict a protein to be 
structurally disordered based partially or completely on amino acid composition and properties 
(charge, hydrophobicity, accessibility by the solvent).  
Using the sequence of TPPP/p25, the Predictor of Natural Disordered Regions (PONDR) 
algorithm was used to characterize the disordered state of the protein (Fig. 2). The PONDR VL-
XT (Romero et al. 1997) considers a region to be disordered if there is at least a 40 aa long 
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continuous sequence above the threshold of 0.5 (Romero et al. 2001). The graph shows the 
predicted disorder scores as the function of sequence. This value can vary between 0 and 1 
according to the probability that a given amino acid is a part of a disordered region. The 52 aa long 
region in the N-terminus of TPPP/p25 is considered to be disordered (PONDR score ~1), while 
the algorithm shows that the middle part of the protein is more ordered, approximately 40 residues 
are definitely below the threshold (PONDR score ~0). Clear conclusion cannot be drawn from the 
values of the C-terminus, the shorter sections alternate. Overall, PONDR predicts TPPP/p25 as 
disordered (45.66%). TPPP/p25 was characterized as an IDP (Hlavanda et al. 2002, Orosz et al. 
2004). 
 
 
Fig. 2. PONDR VL-XT prediction of structural disorder of TPPP/p25. Disorder prediction values 
(PONDR scores) for a given residue are plotted against the residue number. The significance threshold is 
shown (0.5), above which residues are considered to be disordered. 
 
Different experimentally proven characteristics of TPPP/p25 (heat stability, high pI, 
proteolytic sensitivity) also suggested that this protein belongs to the group of IDPs. Circular 
dichroism (CD) revealed largely random coil conformation with some -helix content (Hlavanda 
et al.  2002); Dichroweb (Whitmore et al. 2004) analysis of the spectrum (Fig. 3) showed 14% -
helix, 26% -sheet and 57% disordered region in TPPP/p25. 
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Fig. 3. Dichroweb plot for TPPP/p25. Measured circular dichroism (CD) spectrum of TPPP/p25 (green), 
reconstructed data (blue), and the difference (magenta) are shown. For the analysis, SELCON3 was used 
with protein data set SET7 (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml). 
 
These data were further corroborated by multinuclear nuclear magnetic resonance (NMR) 
analysis, which showed that extended unstructured segments of TPPP/p25 are localized at the N-
(45 aa) and C-termini (44 aa) straddling a flexible region (130 aa) (Zotter et al. 2011a).  
 
3.2.2. Segments of TPPP/p25 involved in its interactions  
 
TPPP/p25 can be phosphorylated in vitro on multiple sites by the Cdk5, ERK2 and PKA 
kinases (Fig. 4) (Hlavanda et al. 2007). It was identified from bovine brain extract as an ERK2 
binding protein. The kinase regulates TPPP/p25 activity via the phosphorylation of Thr14 and/or 
Ser18 localized in the unfolded N-terminal tail: the phosphorylation inhibits its tubulin 
polymerization promoting activity, which resulted in aggregates of tubulin instead of intact-like 
MTs (Hlavanda et al.  2007).  
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Fig. 4. Schematic representation of the FL (219 aa) TPPP/p25. (Modified from Zotter et al. 2011b) 
 
Potential binding segments of TPPP/p25 have been predicted and identified. A GTP 
binding motif on TPPP/p25 was predicted in silico: TPPP/p25 contains four GTP binding motifs, 
three are localized within the flexible region (G68-(X)4GK, D
82-(X)10-T, E
46XSAL) and one 
(D181XXG/D197XXG) within the C-terminus; the GTP binding was supported experimentally by 
size exclusion chromatography and NMR studies (Zotter et al. 2011a). TPPP/p25 displays a 
GTPase activity, it hydrolyses GTP specifically in a magnesium dependent manner (Zotter et al. 
2011a). The protein also has a zinc finger motif (His2Cys2) (His
61-Cys83) and the binding of Zn2+ 
causes a structural alteration inducing the formation of a molten globule (Zotter et al. 2011b). Zn2+ 
as a specific bivalent cation enhances the TPPP/p25-promoted tubulin polymerization (Zotter et 
al. 2011b). 
 
3.2.3. Dimerization potency  
 
TPPP/p25 has a molecular mass of 23.7 kDa. This disordered protein can be detected as 
a single band at ~ 25 kDa in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (Fig. 5.) under reducing circumstances (in the presence of 2-mercaptoethanol (ME)). 
However, it was an early recognition that at non-reducing conditions, another band at ~ 50 kDa 
can also be observed on the gel.  
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Fig. 5. SDS-PAGE of 10 μg TPPP/p25 under reducing and non-reducing conditions. Lane 1: molecular 
weight marker; Lane 2: TPPP/p25, Lane 3: TPPP/p25 in the presence of ME; Lane 4: TPPP/p25 treated 
with the cross-linker N, N′-1,3-phenylenedimaleimide (PDM) in the presence of ME (Oláh et al. 2012). 
 
The protein has three cysteine residues (Fig. 4.), rendering it possible to form both intra- 
and intermolecular disulfide bonds.  Indeed, it has been proved that TPPP/p25 forms dimers, 
stabilized by intermolecular disulfide bridges, which can be diminished by the addition of reducing 
agents (Fig. 1Fig. 5) (Oláh et al. 2012).  
The dimerization of TPPP/p25 is promoted not only by the elevation of protein 
concentration, but also by the addition of GTP (Oláh et al. 2012) or zinc ions (Lehotzky et al. 
2015). Biophysical measurements showed that the monomers undergo a conformational change, a 
partial folding in the course of their dimerization: the likely unfolded monomer becomes an 
apparently more folded, compact dimer (Oláh et al. 2012). Chemical cross-linking of SH groups 
revealed that the stabilized dimeric form displays enhanced tubulin polymerization promoting 
activity as detected by turbidity measurements (Fig. 6) (Oláh et al. 2012).  
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.  
Fig. 6. The effect of dilution on the TPPP/p25-induced tubulin polymerization. The polymerization was 
induced by the addition of an aliquot of TPPP/p25 stock solution (400 μM) to tubulin (bold line) or by the 
addition of tubulin to TPPP/p25 incubated in the cuvette (solid line). Final concentration of TPPP/p25 
was 3 μM, while that of tubulin was 7 μM (modified from Oláh et al. 2012). 
 
3.2.4. Intracellular localization 
 
TPPP/p25 was described to be expressed predominantly in the OLGs, neuropil in rat brain 
(Takahashi et al. 1993, Skjoerringe et al. 2006) and in human brain as well (Fig. 7) (Kovács et al. 
2004, Höftberger et al. 2010).  
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Fig. 7. A. Immunohistochemical staining for TPPP/p25 demonstrates its immunopositivity in OLG. B. 
Electron microscopic image of OLG shows TPPP/p25-specific immunogold particles in the cytoplasm 
(Höftberger et al. 2010). 
 
The expression of TPPP/p25 is crucial for the differentiation of OLGs (Fig. 8) as 
demonstrated by means of siRNS as well as specific microRNA (mir206), which down-regulate 
its expression (Lehotzky et al. 2010). TPPP/p25 is able to stabilize the MT network during the 
elongation of projections in the course of differentiation, which is an essential process, since the 
differentiated OLGs are the major constituents of the myelin sheath around the axons.  
 
 
Fig. 8. TPPP/p25 co-localizes with microtubules in differentiated OLG (CG-4) cells. The cells were 
immunostained for tubulin (red) and TPPP/p25 (green), Scale bar = 10 μm (Lehotzky et al. 2010). 
 
When TPPP/p25 is expressed ectopically in HeLa cells, which is a cell line derived from 
human cervical adenocarcinoma, the protein is aligned along the MT network resulting in 
extensive MT bundling; the MT system becomes resistant against anti-MT treatment (nocodazole 
or cold treatment, Lehotzky et al. 2004). Despite its stabilization effect, the association of 
18 
TPPP/p25 to the bundled MTs is highly dynamic, as demonstrated by fluorescence recovery after 
photobleaching (Lehotzky et al. 2004).  
As a disordered protein, TPPP/p25 is degraded by the proteasome machinery as 
demonstrated in HeLa cells transfected with enhanced green fluorescent protein fused with 
TPPP/p25 (EGFP-TPPP/p25) (Lehotzky et al. 2004). The overall fluorescence intensity of the 
labelled protein was quantified in the absence and presence of MG132, a proteasome inhibitor 
(Carbobenzoxy-Leu-Leu-Leu-al). In the presence of the inhibitor, significant increase of the 
EGFP-TPPP/p25 level was detected, which is indicative for the role of proteasome in the 
proteolytic degradation of TPPP/p25 (Goldbaum et al. 2008).  
 
3.2.5. TPPP/p25 in pathological context 
 
The intracellular TPPP/p25 level affects the structural organization of the MT system 
(Lehotzky et al. 2004): at low expression level the protein aligns along the MT network (Fig. 9., 
cell marked 1), while its overexpression promotes the formation of two distinct pathological 
ultrastructures: the perinuclear cage formed by bundled MTs around the nucleus (Fig. 9., cell 
marked 2) and the aggresome at the centrosomal region (Fig. 9., cell marked 3).  
 
 
Fig. 9. HeLa cells transfected with pEGFP-TPPP/p25. (A) The representative image shows three 
TPPP/p25-transfected cells with distinct morphologies in the same microscopic field. Note the co-
localization (orange) of EGFP-TPPP/p25 (green) with the MT network (red) at low expression levels (cell 
marked 1). The other two cells with bright fluorescence show an aberrant MT network and morphological 
changes with co-localization (marked 2 and 3) (Lehotzky et al. 2004). 
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The aggresome mimics the pathological inclusions of the brain (Kopito 2000). 
Aggresome formation may serve as a protective mechanism against the small toxic aggregates 
(Kawaguchi et al. 2003), which are located at the cell peripheries; these toxic aggregates are 
transported to the perinuclear aggresome, which is a site for the recruitment of the ubiquitin 
proteasome system components (Corboy et al. 2005). 
 The multifunctional TPPP/p25 is involved in different pathological processes. Its non-
physiological level in human brain is coupled with the development of distinct CNS diseases (Fig. 
10.).   
 
Fig. 10. Consequences of the distinct expression of the NMP TPPP/p25. 
 
In the case of oligodendroglioma, the lack of TPPP/p25 was observed in the human brain 
(Preusser et al. 2007). The division of the progenitor cells is extensive in glioma, while the 
presence of TPPP/p25 would block mitotic spindle formation and help differentiation (Tirián et al. 
2003). In multiple sclerosis, which is an idiopathic chronic inflammatory demyelinating disease of 
the CNS, altered TPPP/p25 levels were found in the affected regions of the brain (Höftberger et 
al. 2010) coupled with elevated TPPP/p25 levels in the cerebrospinal fluid (Vincze et al. 2011). 
TPPP/p25 interacts with -amyloid, producing aggregates that has been detected in a phenotype 
of diffuse Lewy body dementia with Alzheimer’s disease (Oláh et al. 2011).   
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The pathological interaction of TPPP/p25 with SYN, the hallmark protein of 
synucleinopathies has been studied most extensively. Substoichiometric TPPP/p25 concentration 
induces the formation of SYN fibers (Lindersson et al. 2005). The co-enrichment and co-
localization of the two proteins were found in neuronal inclusions of PD and diffuse Lewy body 
disease, as well as in glial inclusions in MSA (Kovács et al. 2004), and hallmarking feature of 
TPPP/p25 as marker of synucleinopathies was reported (Kovács et al. 2004).  
 
3.2.6. The moonlighting feature of TPPP/p25 
 
This protein belongs to the group of moonlighting proteins that perform multiple 
functions without any alterations at genetic level (Jeffery 1999). Despite the one gene-one function 
paradigm, these proteins display distinct functions due to changes in their cellular localization, cell 
type, conformations, oligomeric states or hetero-associations (Jeffery 1999). Protein moonlighting 
differs from simple protein multifunctionality, in which different domains of the same protein 
display different functions because of gene fusion or exon shuffling (Piatigorsky et al. 1989). 
Moonlighting is characteristic for many IDPs (Sickmeier et al. 2007), since these proteins do not 
have a stable 3D structure and can undergo disorder-to-order transitions upon binding (Fink 2005, 
Tompa et al. 2005). 
TPPP/p25 is not only known as a modulating and stabilizing factor of the MT network, it 
promotes tubulin acetylation by inhibiting the activity of tubulin deacetylases such as sirtuin2 
(SIRT2) and histone deacetylase 6 (HDAC6) (Tőkési et al. 2010, Mangas-Sanjuan et al. 2015).  
TPPP/p25 is the prototype of the NMPs (Ovádi 2011, Oláh et al. 2013), which display 
distinct functions under physiological and pathological conditions due to their interactions with 
distinct protein partners (Jeffery 2011). Its main physiological partner is the tubulin/MT, while 
under pathological conditions it interacts with SYN resulting in aggregation, which ultimately 
leads to cell death. 
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3.3. A hallmark of synucleinopathies: -synuclein 
 
SYN (Weinreb et al. 1996) is a small protein (140 aa long) that is expressed 
predominantly in the neurons of the CNS and in red blood cells (Barbour et al. 2008). It is highly 
soluble, found mainly in the cytosol and the presynaptic terminals near synaptic vesicles; it makes 
up 0.5%-1.0% of the total cytosolic proteins in brain homogenates (Iwai et al. 1995). SYN is an 
IDP, although it can adopt various conformations under both physiological and pathological 
conditions, including induced folding in lipid membranes, self-aggregation and fibril formation 
(Silva et al. 2013). This protein is the hallmark of synucleinopathies comprising PD, Lewy body 
dementia as well as MSA. 
 
3.3.1. High conformational plasticity of -synuclein 
 
Structural disorder predicting algorithms indicate that the C-terminal segment of SYN is 
disordered. PONDR analysis shows 37% overall disorder for the protein. Its amino acid 
composition is characteristic for IUPs (complete lack of Trp and Cys, very high Glu content), along 
with its low aromaticity and high net charge (-10) (Orosz et al. 2004 and references therein). It has 
a long, fully disordered segment on its C-terminus, as well as a minor region on the N-terminus of 
the protein (Fig. 11.). Its central region (60-90 aa) cannot be identified as ordered or disordered 
unambiguously.  
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Fig. 11. PONDR VL-XT analysis of SYN. Disorder prediction values (PONDR scores) for a given 
residue are plotted against the residue number. The significance threshold is shown (0.5), above which 
residues are considered to be disordered. 
 
The disordered nature of SYN has been extensively characterized experimentally as well, 
with numerous methods including CD, NMR, SDS-PAGE and analytical gel filtration (Eliezer et 
al.  2001, Fauvet et al. 2012). 
The protein is composed of three functionally defined regions (Fig. 12). The N-terminal 
region (1-60 aa) contains a unique, highly conserved apolipoprotein lipid-binding motif of 4x11 
imperfect tandem repeats (KTKEGV). The central hydrophobic region (61-95) confers the β-sheet 
potential (Uéda et al. 1993) and contains the sequence (71-82) necessary and sufficient for its self-
assembly into amyloid fibrils (Giasson et al. 2001). The highly disordered C-terminus (96-140) is 
rich in negatively charged amino acids (10 Glu, 5 Asp). The presence of the five structure disruptor 
Pro on the C-terminus indicates its disordered state (George et al. 1995, Ulmer et al. 2005). SYN 
can be phosphorilated on Ser residues 87 and 129, with the latter being the predominant site, by 
casein kinases 1 and 2 (Okochi et al. 2000), as well as by G-protein-coupled receptor kinases; 
phosphorylation inhibits its interaction with phospholipids (Pronin et al. 2000).  
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Fig. 12. Schematic representation of the 140 aa SYN. Several pathogenic mutations as well as the 
phosphorylation sites are indicated (modified from Bellucci et al. 2012). 
 
Although SYN is predominantly unfolded at physiological conditions, in response to 
changes in its environment (low pH, high temperature, organic solvents, membranes, 
agrochemicals, or metal ions), it is capable of adopting structurally unrelated conformations, 
ranging from intrinsically disordered form to various partially folded conformations with different 
contents of secondary structural elements (Uversky 2003, Silva et al. 2013). The structure of the 
membrane bound vesicular SYN contains two α-helices with a short linker region (3-37 and 45-
92) in a roughly antiparallel arrangement (Ulmer et al. 2005, Davidson et al. 1998) and it was 
proposed that during this transition a multimeric SYN is formed (Burré et al. 2014, Luth et al. 
2015). The native oligomeric state of the protein is still a matter of debate due to conflicting reports 
considering the protein either monomeric or tetrameric (Bartels et al. 2011, Dettmer et al. 2013, 
Fauvet et al. 2012).  
 
3.3.3. Physiological aspects 
 
SYN was first co-purified with synaptic vesicles from the Torpedo electric ray 
(Maroteaux et al. 1988), and later it was found to be localized in the presynaptic terminals of 
neurons in the mammalian CNS (Iwai et al. 1995). These results indicated that its functions are 
related to neurotransmission and the modulation of vesicular synaptic release (Murphy et al. 2000). 
Direct evidence of interaction was reported by co-immunoprecipitation of SYN with the vesicle 
fusion mediator SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor, 
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Ungar et al. 2003) proteins involved in intracellular trafficking (Burré et al. 2010). SYN was found 
to dose-dependently facilitate the SNARE complex assembly, binding specifically to the vesicular 
SNARE protein synaptobrevin-2 (Diao et al. 2013), which emphasizes its role in vesicular 
membrane transport. Despite extensive research, the physiological properties and functions 
of SYN are still poorly understood.  
Interestingly, a small amount of SYN is secreted from the cells and present in certain 
body fluids, such as the cerebrospinal fluid (El-Agnaf et al. 2006, Tokuda et al.  2006). The 
aggregates are also internalized via endocytosis and could be degraded by the lysosomal pathway, 
while the monomeric form is proposed to translocate across the membranes freely (Lee et al. 2008). 
Further experiments have shown that both the free and the aggregated SYN can be secreted and 
taken up by neurons, and cell-to-cell transmission can occur among neurons and multiple glial cell 
types, including OLG (Bates et al. 2014).  
 
3.3.4. Pathological relevance  
 
The etiology of the conformational diseases is a multistep process, initiated by unfolded 
and/or misfolded proteins forming aberrant protein-protein interactions and insoluble polymeric 
structures and aggregates, which finally leads to the formation of inclusions then cell death 
(Dobson 1999). The aggregation of IDPs are characteristic (Uversky 2014, Uversky 2015) for 
tauopathies (-amyloid and/or tau) such as Alzheimer’s and Pick’s disease (Lee et al. 2012); prion 
diseases (prion protein, Safar 2012); Huntington’s disease (mutant huntingtin, Arrasate et al. 2012) 
and synucleinopathies such as PD, MSA and dementia with Lewy bodies in which SYN is the 
main constituent of Lewy bodies and glial cytoplasmic inclusions (Stephanis 2012, Vieira et al. 
2015, Kim et al. 2014). 
PD (Parkinson 1817, reprinted in 2002, Beitz 2014) is the second most common 
neurodegenerative disorder after Alzheimer's disease, with a prevalence of approximately 0.5 to 1 
percent in the age of 65 to 69, rising to 1 to 4 percent among persons 80 years of age and older (de 
Lau et al. 2006); which presents a growing socio-economic problem with the aging of society. It 
is not considered as a fatal disease: PD is slowly progressive, coupled with motor symptoms 
(tremor, bradykinesia, rigidity and postural instability); its development irreversibly decreases the 
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quality of the patient’s life. The disease is characterized by a relatively selective loss of 
dopaminergic neuronal cells (Chinta et al. 2005, Surmeier et al. 2010) of the substantia nigra pars 
compacta and the appearance of intracellular, fibrillar inclusions of SYN, TPPP/p25 and additional 
proteins in the affected surviving neurons (Wakabayashi et al. 2013).  
MSA also belongs to the group of synucleinopathies. It is characterized by 
oligodendroglial cytoplasmic inclusions (Jellinger et al. 2016), where SYN was found to be co-
localized with TPPP/p25 (Kovács et al. 2004). The relocation of TPPP/p25 from myelin to OLG 
and its aggregation preceded the accumulation of SYN (Song et al. 2007, Ota et al. 2014) and was 
followed by the hetero-association of the two proteins, which resulted in aggregation and the 
formation of inclusion bodies mainly consisting of SYN (Arima et al. 1998, Ota et al. 2014, 
Jellinger et al. 2016).  
SYN plays pathological roles in mixed type Alzheimer’s disease as well (Hansen et al. 
1990, Hamilton 2000); these observations make the protein a target of excessive research.  
Current research states that the small, soluble oligomeric forms with beta-sheet structure 
are considered the most toxic species (Dehay et al. 2015, Roberts et al. 2015, Winner et al. 2011). 
Although knowledge on various mechanisms underlying PD and other synucleinopathies has been 
greatly expanded over the last decades, the pathomechanism is still not well-understood (Dehay et 
al. 2015, Ozansoy et al. 2013, Roberts et al. 2015).  
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4. MATERIALS AND METHODS 
 
4.1. DNA manipulation 
 
The TPPP/p25 (N-, C-, double truncated and fluorescently labeled) forms and the SYN 
(SYN1-120 and SYN95-140) mutants were produced by N. Tőkési and T. Szénási as described (Tőkési 
et al. 2014, Szunyogh et al. 2015, Szénási et al. 2017) with the following sequences: 3-43 
TPPP/p25 (N-truncated, N TPPP/p25), 175-219 TPPP/p25 (C-truncated, C TPPP/p25) and 
3-43/175-219 TPPP/p25 (double truncated, CORE) form. Both the EGFP-TPPP/p25 and the 
EGFP-CORE constructs contain the EGFP on the N-terminal region of the proteins, as well as the 
Venus constructs the Venus fragments (Scheme 1). The sequences of all constructs were verified 
by restriction mapping and DNA sequencing. 
 
 
Scheme 1. The Venus constructs of the FL and the CORE TPPP/p25 forms. 
. 
4.2. Recombinant protein preparation 
 
The proteins were expressed in E. coli BL21 (DE3). 25 µL stock solution of transformed 
E. coli expressing a TPPP/p25- or SYN-variant (30%glycerol in Luria Bertani Broth (LB, 20 g/l) 
containing the E. coli) were inoculated into 5 ml sterile LB with 0.1 mg/ml ampicillin and 0.1 
mg/ml chloramphenicol then grown overnight at 37°C with a shake rate of 220 rpm. The starter 
culture was added to 300 ml LB with 0.1 mg/ml ampicillin and was grown until it reached the 
optical density of 0.4-0.6 at 600 nm, when they were induced with 1 mM isopropyl β-D-1-
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thiogalactopyranoside (IPTG, Sigma-Aldrich) for 3 h at 37°C, then harvested by centrifugation for 
15 min at 4°C at 2500 g.  
The TPPP/p25 forms and SYN95-140 contain a 6xHis tag. In these cases, the pellet was 
suspended in a lysis buffer containing 50 mM Na2HPO4 and 300 mM NaCl pH 7.4 supplemented 
with protease inhibitor mix (1 mM benzamidine, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF)) and 1 mg/ml lysozyme. The sample was sonicated for 
6x15 s with 30 s intervals on ice, and centrifuged for 40 min at 4°C at 100,000 g. The supernatant 
was loaded to a HIS-Select® Nickel Affinity Gel column (Sigma-Aldrich), which was previously 
equilibrated with lysis buffer. The Ni2+ ions selectively bound the 6xHis tag on the proteins. The 
column was washed extensively, then the proteins were eluted with 50 mM sodium acetate, 300 
mM NaCl pH 4.5. The drastic change in the pH caused the Ni2+ to release the 6xHis tag. The eluted 
proteins were concentrated in an Amicon (Millipore) stirred cell with ultrafiltration membranes 
with nominal molecular weight limit (NMWL) of 10,000 Da for the FL, the C and N TPPP/p25 
forms and of 3000 Da for the CORE TPPP/p25 and SYN95-140 to a concentration close to 1 mg/ml. 
The pellet of SYN and SYN1-120 were resuspended with lysis buffer containing 20 mM 
Tris-HCl, 50 mM NaCl (10 mM NaCl in the case of SYN1-120), 1 mM ethylenediaminetetraacetic 
acid (EDTA), 5 mM ME pH 7.5 (pH 8.0 in the case of SYN1-120) supplemented with protease 
inhibitor mix and 1 mg/ml lysozyme. The sample was sonicated for 6x15 s with 30 s intervals on 
ice, and centrifuged for 25 min at 4°C at 39,000 g. The supernatant was kept at 85°C for 10 min, 
since SYN is heat stable (Park et al. 2002), then centrifuged for 25 min at 4°C at 39,000 g. The 
soluble part is mainly consisted of SYN. It was loaded to a Whatman® anion exchange cellulose 
DE52 column, which was previously equilibrated with lysis buffer. The column was washed 
extensively, then the proteins were eluted with lysis buffer containing 150 mM NaCl. The eluted 
proteins were concentrated in an Amicon (Millipore) stirred cell with ultrafiltration membranes 
with NMWL of 3000 Da. The differences in the salt concentration and pH of the buffer in the case 
of the two SYN forms are related to the sequence alteration: the last highly acidic amino acids are 
missing from SYN1-120 resulting in a weaker binding to the used anion exchange column. 
The concentrated proteins were dialyzed overnight in 50 mM ammonium acetate then 
lyophilized and stored at -80°C. The purity of the preparation was determined by SDS-PAGE.  
Protein concentration was determined from the absorbance at 280 nm using an extinction 
coefficient of 10095 M−1 *cm−1, 10095 M−1 *cm−1, 5625 M−1 *cm−1, 5625 M−1 *cm−1, 5960 M−1 
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*cm−1, 2980 M−1 *cm−1 and 4470 M−1 *cm−1 for TPPP/p25, N TPPP/p25, C TPPP/p25, CORE 
TPPP/p25, SYN, SYN1-120 and the C-terminal SYN95-140, respectively. Extinction coefficients were 
calculated using ProtParam (http://web.expasy.org/cgi-bin/protparam/protparam). 
 
4.3. Tubulin preparation from bovine brain 
 
The MAP free tubulin was purified from bovine brain according to Na and Timasheff (Na 
et al. 1986). All preparation steps were conducted in a cold room at 4°C. The cleaned brain was 
homogenized in lysis buffer (10 mM Na2HPO4, 0.24 M sucrose, 0.1 mM GTP, 1 mM 
dithioerythritol (DTE), 1 mM PMSF, pH 7.0) and centrifuged for 30 min at 4°C at 11,000 g. The 
supernatant was precipitated with 187 g/L, 32 % (NH4)2SO4 and centrifuged for 30 min at 4°C at 
15,000 g. Again, the supernatant was precipitated with (NH4)2SO4 (+71 g/L, 43%). This is the step 
where tubulin is precipitated along with its MAPs. The solution was centrifuged for 30 min at 4°C 
with 15,000 g, then the precipitate was suspended in washing buffer (10 mM Na2HPO4, 0.1 mM 
GTP, 1 mM PMSF, 1 mM DTE, pH 7.0). A DEAE Sephadex A-50 anion exchanger column was 
equilibrated with the washing buffer, then the tubulin containing solution was loaded onto it. The 
MAPs were removed with a washing buffer containing 0.4 M KCl. The elution was performed 
with washing buffer supplemented with 0.8 M KCl. After this, another precipitation was carried 
out with 24.8 g/L (NH4)2SO4. The sample was centrifuged for 30 min at 4°C at 33,000 g. The pellet 
was resuspended in minimal buffer volume and was loaded into a Sephadex G-50 column to 
remove the excess salt, then dialyzed into a buffer of 10 mM Na2HPO4, 1 M sucrose, 0.5 mM 
MgCl2, 0.1 mM GTP, pH 7.0 for storage at -80°C. Concentration was measured in 0.1 M NaOH 
at 280 nm, purity was verified with SDS-PAGE and the functional properties of the tubulin was 
measured by turbidimetry.  
 
4.4. SDS-PAGE 
 
The gel electrophoresis was carried out by the Laemmli method (Laemmli et al. 1970), 
which separates the denatured proteins by their molecular weight. The standard stacking gels 
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contained 13.5% acrylamide/bis-acrylamide (37.5:1 ratio); the sample contained 20% loading 
buffer (1,2% SDS, 0,025% bromophenol blue, 40% glycerol and 10% ME if reducing 
circumstances were needed). The molecular weight marker PageRuler Prestained Protein Ladder 
was obtained from Thermo Scientific. BioRad Mini-Protean II electrophoresis cell was used for 3 
h at 100 V, room temperature (RT). The gels were fixed with a buffer of 10% acetic acid and 25% 
isopropanol for 30 min then washed for 3x10 min, followed by overnight staining with PageBlue 
Protein Staining Solution (Thermo Scientific). 
The Tricine-containing two-layer-gel was made according to the method of Schägger and 
von Jagow (Schägger et al. 1987) for low molecular weight proteins. The separating gel was 7%. 
 
4.5. Antibodies, peptides 
 
The following antibodies were used: monoclonal mouse TPPP/p25 antibody (Höftberger 
et al. 2010), and its biotinylated form produced by T. Berki (Höftberger et al. 2010); rat polyclonal 
TPPP/p25 antibody (Kovács et al. 2004); mouse monoclonal SYN antibody against the epitope of 
121-125 aa (Sigma Aldrich, S5566, clone Syn211); rabbit polyclonal SYN antibody developed 
against the 111-132 peptide sequence in the C-terminus of the protein (Sigma Aldrich, S3062); 
rabbit monoclonal SYN antibody developed against the N-terminus of SYN (Merck, 04-1053, 
clone EP1646Y) and mouse monoclonal tubulin antibody (Sigma Aldrich, T6199, clone DM1A). 
The peptides BF180-183 and P1-P4 were synthesized in collaboration with A. Magyar in 
the Research Group of Peptide Chemistry, ELTE. In the case of BF183 and BF180, a Lys was built 
into the C-terminus of the peptides to conjugate the biotin derivative to its side chain (ε-amino 
group). The biotinylated forms were prepared using biotinyl-6-amino-hexanoic acid (long chain 
biotin). The N-terminus of the peptides was acetylated, while the C-terminus was in amide form. 
For the P1-P4 peptides, a Cys was built into the N-terminus. The N-terminus of the peptides was 
acetylated, while the C-terminus was in amide form. The SYN126-140 peptide 
(EMPSEEGYQDYEPEA) and its fluorescein-labeled form (FITC-EMPSEEGYQDYEPEA) were 
purchased from ChinaPeptides (Shanghai, China). 
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4.6. Turbidity measurements 
  
The assembly of 7 µM tubulin was assessed in polymerization buffer (50 mM MES buffer 
pH 6.6 containing 100 mM KCl, 1 mM DTE, 1 mM MgCl2 and 1 mM EDTA) at 37°C in a 500 l 
cuvette. The polymerization of tubulin was induced by addition of 3 µM wild type TPPP/p25 or 
its truncated forms with the addition of 100 µMnCl2 where indicated. When TPPP/p25 was 
diluted into the cuvette with or without ZnCl2, it was incubated for 10 minutes and the 
polymerization was initiated by a stock solution of tubulin, otherwise the polymerization was 
induced by the addition of TPPP/p25 or its forms from 10 mg/ml stock. 
The MT bundling experiments were conducted in polymerization buffer at 37°C, where 
10 M tubulin was polymerized into MTs by the induction of 20 M paclitaxel, then subsequently 
3 M TPPP/p25 or one of its forms was added to the solution to examine the bundling activities.  
At least three independent experiments were performed. A representative polymerization 
is shown; error of determinations (SEM) is ± 10%. The turbidity was monitored at 350 nm by a 
Cary 100 spectrophotometer (Varian, Walnut Creek, Australia). 
 
4.7. Pelleting experiment 
  
5 M tubulin was incubated with 10 M of the different TPPP/p25 forms for 10 min at 
37°C in polymerization buffer, then centrifuged for 15 min at 37°C at 17,000 g and the pellet and 
supernatant fractions were separated. The pellet fraction was washed and resuspended in 
polymerization buffer. The pellet and the supernatant fractions were analyzed by Tricine SDS-
PAGE with loading buffer containing ME. The distributions of 2 g TPPP/p25 forms and 4 g 
tubulin were analyzed in the fractions. 
In the case of MT pelleting, 20 M tubulin was polymerized with 20 M paclitaxel for 
30 min at 37°C in polymerization buffer, then centrifuged for 15 min at 37°C at 17,000 g and the 
pellet and supernatant fractions were separated. The pellet fraction was washed and resuspended 
in 20 M paclitaxel containing polymerization buffer. 1 mg/ml MT (10 M tubulin) were 
incubated with 10 M TPPP/p25 forms for 15 min at 37°C, then centrifuged for 15 min at 37°C at 
17,000 g. The pellet and the supernatant fractions were analyzed by SDS-PAGE with loading 
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buffer containing ME. The distributions of 3.75 g TPPP/p25 forms and 15 g tubulin were 
analyzed in the fractions. 
 
4.8. Enzyme linked immunosorbent assay (ELISA) and cellular ELISA (cELISA) 
 
The 96-well plate was coated with 5 g/ml (100 l/well) TPPP/p25 or SYN forms in 
phosphate buffered saline (PBS) or in case of the biotinylated peptides with 5 g/ml (100 l/well) 
streptavidin solution in PBS overnight at 4°C. The wells were blocked with 1 mg/ml bovine serum 
albumin (BSA) in PBS for 1 hour at RT. The next step was the serial dilution or constant amount 
of the partner(s) as indicated in each experiment for 60 min with or without a preincubation of 
partners for 30 min. It was followed by the addition of either tubulin, SYN or TPPP/p25 antibody, 
and the addition of the peroxidase conjugated secondary IgG (1:5000, Sigma-Aldrich), both in 
PBS buffer containing 1 mg/ml BSA for 1 h. Dilutions were usually 1:5000, for the monoclonal 
mouse TPPP/p25 antibody it was 1:1000, in the cases of the mouse monoclonal and the rabbit 
monoclonal SYN antibodies it was 1:2000.  Between each incubation step, the wells were washed 
thrice with PBS containing 0.05% Tween 20 (Sigma Aldrich). The bound antibodies were detected 
using ortho-phenylenediamine as substrate in the concentration of 3.7 mM with 0.03% H2O2 as 
substrate solution. The reaction was stopped after 10 min with 1 M H2SO4 and the absorbance was 
read at 490 nm with a Wallace Victor 2 multiplate reader (Perkin Elmer) or an EnSpire Multimode 
Reader (Perkin Elmer). The apparent binding constants (Kd) were evaluated from the saturation 
curves, using non-linear curve fitting, assuming a single binding site hyperbola model using the 
Origin v8.0 software. Error bars represent the standard error of the determinations (SEM) (n= 3). 
* Significant difference, according to Student's t-test, p<0.05.  
Differences from this protocol: In the case of P1-P4 peptides: Sulfhydryl-BIND™ 
(Maleimide) Modified Surface plate (Corning Incorporated) was used according to the 
manufacturer’s instructions. The plate was coated with 5 g/ml (100 l/well) peptide or TPPP/p25 
solution in PBS buffer containing 1 mM EDTA pH 6.5 for 1 hour at RT. The next step was the 
blocking with 0.2% non-fat dry milk in PBS for 30 min at RT. Then the place was incubated with 
tubulin as described above.  
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Sandwich ELISA: The plate was coated with 1 g/mL (50L/well) mouse monoclonal 
TPPP/p25 antibody in 200 mM Na2CO3 buffer pH 9.6 overnight at 4°C. The wells were blocked 
with 1 mg/mL BSA in PBS for 1 hour at RT. Then the plate was incubated with serial dilutions of 
5 M TPPP/p25 for 1 hour at RT. Then the plate was sequentially incubated with biotinylated 
monoclonal TPPP/p25 antibody (1 µg/mL) and peroxidase conjugated avidin (Calbiochem) (2.5 
µg/mL). 
cELISA: After manipulation, the cells in the 96-well tissue culture plate were fixed by 
ice cold methanol for 10 min. The fixed cells were rehydrated by PBS, and blocked with 1 mg/mL 
BSA in PBS containing 0.1% Triton-X-100 (Sigma Aldrich) for 1 hour at RT. Then the plate was 
sequentially incubated with mouse monoclonal TPPP/p25 antibody (1.5 µg/mL ~1:750) and with 
an anti-mouse IgG-peroxidase conjugate (1:2500, Sigma Aldrich) in PBS containing 1 mg/mL 
BSA and 0.1% Triton-X-100 for 1 hour at RT. Following each incubation step, the wells were 
washed thrice with PBS for 5 min. The relative TPPP/p25 concentration was quantified by using 
o-phenylenediamine in the concentration of 3.7 mM with 0.03% H2O2 as substrate. The reaction 
was stopped after 15 min with 1 M H2SO4; absorbance was read at 490 nm with an EnSpire 
Multimode Reader (Perkin Elmer). 
 
4.9. Circular dichroism spectroscopy 
 
 The CD measurements were performed on Jasco J-720 spectropolarimeter at 20 nm/min 
scan rate, 8 s time constant and 0.5 nm step size in 10 mM phosphate buffer, pH 7.2 at RT, the 
cuvette path length was 0.1 cm. The protein concentrations were 4 μM for TPPP/p25 forms and 1 
μM for tubulin. The mixtures were incubated for 10 min before recording the spectra. Scanning 
was repeated three times, and the spectra were averaged. Difference of ellipticity (in millidegrees) 
was calculated by subtracting the ellipticities of TPPP/p25 or its forms and tubulin from that 
measured with their mixture. Mean molar ellipticity per residue () in degree square centimeter 
per decimole was calculated according to the following equation:  = m/(10*n*c*l), where m 
is the measured ellipticity in millidegrees, n is the number of amino acid residues, c is the 
concentration in moles and l is the path length of the cuvette in centimeters. The standard error of 
the determinations (SEM) was ± 10% (n = 3-5). 
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4.10. Affinity chromatography  
 
SYN was immobilized to CNBr-activated Sepharose 4B (Amersham) according to the 
manufacturer’s instructions. SYN bound to the resin beads was packed into columns. The binding 
capacity of a column was ~1.5 mg SYN per 1 ml resin (column volume ~ 2 ml). The affinity 
column was equilibrated with phosphate buffer (10 mM phosphate pH 7.4 containing 10 mM 
NaCl). 500 g TPPP/p25 with or without 500 g SYN or SYN1-120 was loaded to the column in 
the volume of 500 l, then the column was washed with phosphate buffer (10 ml, 1 ml fractions). 
The bound proteins were eluted with phosphate buffer containing 100 mM NaCl (5 ml, 1 ml 
fractions). After each experiment the column was regenerated using 3 cycles of 0.1 M Na-acetate 
pH 4.0 buffer containing 0.5 M NaCl and 0.1 M tris(hydroxymethyl)aminomethane (Tris) pH 8.0 
buffer containing 0.5 M NaCl. The flow-through (unbound) and the eluted (bound) fractions were 
analyzed by SDS-PAGE.  
 
4.11. Cell culture and manipulation   
 
The following cell lines were used: CHO10, which is a tetracycline-inducible TPPP/p25 
expressing CHO-K1 Tet-On cell line variant generated in the Cell Architecture research group 
(Tőkési et al. 2010) and the human cervical adenocarcinoma cell line HeLa (ATCC, CCL2). 
Hela cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal 
bovine serum (FBS), 100 unit/ml streptomycin and 100 g/ml penicillin antibiotics (all cell culture 
reagents from Sigma Aldrich); CHO10 cells were cultured in DMEM Nutrient Mixture F-
12 (DMEM/F12) supplemented with 10% tetracycline free FBS, 100 unit/ml streptomycin and 100 
g/ml penicillin antibiotics. The cells were propagated in a humidified incubator at 37°C with 5% 
CO2. Cells were routinely checked for mycoplasma contamination by fluorescence microscopy 
using 4,6-diamidino-2-phenylindole (DAPI) staining. 
The cells were grown on 12 mm diameter coverslips for microscopic analysis (1-2 x 104 
cells per coverslip), on 24-well plates for immunoblotting (2.5-5 x 104 cells per well) and on 96-
well plates for cELISA (0.5-1 x 104 cells per well). After the passage of cells to the 
plates/coverslips, they were incubated overnight in the incubator.  
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The CHO10 cells were treated as follows. For induction, the cells were cultured overnight 
with 100 ng/ml doxycycline (tetracyclin analogue, sub-maximal induction).  Where it is indicated, 
10 µM MG132 (Sigma Aldrich) or 10 µM ZnCl2 (Sigma Aldrich) was added for 3 h.  
For microscopic analysis, the uptake of TPPP/p25 and its CORE form was examined by 
the addition of 2.5 g TPPP/p25 forms or 3 g TPPP/p25 and 12 g SYN forms, when the ability 
of these proteins to aggregate was examined. The proteins were freshly dissolved in PBS. After a 
short preincubation of the SYN and TPPP/p25 forms in 1 mg/ml concentrations, the proteins were 
added to 500 l medium to be taken up by the cells during the 3 h incubation. The final 
concentrations of TPPP/p25 and SYN species were 0.006 mg/ml (0.24 M) and 0.024 mg/ml 
(1.68) M (1/7 ratio), respectively. In the case of the FITC labeled SYN peptide, 1 l of a 10 gl 
(440 M, final concentration is 0.02 mg/ml) stock solution was used with the TPPP/p25 forms.  
The quantification of microscopic image intensities was performed with ImageJ v1.49 
software using the original grayscale pictures. The whole territory of each cell was outlined by the 
Freehand Line tool and integrated pixel densities were calculated by multiplying the area of each 
cell with the corresponding average pixel intensity subtracting the background.  
For the transfection of HeLa cells with the EGFP-TPPP/p25 and EGFP-CORE TPPP/p25 
plasmids and the Venus constructs, the cells were transfected overnight with 0.3 g DNA of each 
plasmid using Turbofect (Thermo Scientific) transfection reagent according to the manufacture’s 
protocol. 
 
4.12. Immunocytochemistry 
 
The HeLa and CHO10 cells on glass coverslips were fixed with ice-cold methanol for 10 
min followed by postfixation with 4% formaldehyde (Sigma Aldrich) for 2 min. After washes with 
PBS (3x10 min), samples were blocked for 30 min in antibody dilution buffer (5% FBS and 0.1% 
Triton X-100 in PBS). For SYN-staining, the buffer contained 30 µM digitonin instead of Triton 
X-100. 
The samples were incubated with primary antibodies against tubulin, TPPP/p25 and SYN 
as indicated (dilutions: mouse monoclonal TPPP antibody 1:1000, rat polyclonal TPPP/p25 
antibody 1:1500, mouse monoclonal SYN antibody 1:1000, rabbit monoclonal SYN antibody 
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1:1000, rabbit polyclonal SYN antibody 1:500). Alexa 488 and Alexa546 conjugated antibodies 
(Invitrogen, 1:1000) were used as dictated by the primary antibody. To detect the FITC-labeled 
peptide, as well as the EGFP or Venus constructs, intrinsic fluorescence was used. The samples 
were washed thrice with PBS for 3x10 min after antibody incubation. Nuclei were counterstained 
with 0.5 g/ml DAPI. Images of fixed samples were acquired on a Leica DM IL 500 microscope 
equipped with Leica DFC 395 FX camera and HBO 100w lamp. The equipment software was 
Leica Application Suite 4.4.0. Chroma UV filter set (No. C40888) was used for DAPI; Chroma 
41028 HQ NB GFP filter set (No. C21116) for EGPF, FITC and Alexa488; Chroma 41028 Y GFP 
filter set (No. C2117) for Venus and Leica filter N2.1 (No. 513832) for Alexa 546 signal 
acquisition, using a HCX FL Fluotar 40x/0.75 (dry) objective, except Fig.24, which was imaged 
on a Zeiss LSM710 confocal microscope. 
Generally, the images presented on the figures were taken under constant exposure 
parameters in a given experiment, except panel D on Fig. 35, where lower exposure time was used 
due to the extreme signal strength of the protein aggregates. 
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5. RESULTS AND DISCUSSION 
 
5.1. PHYSIOLOGICAL INTERACTIONS OF TPPP/p25 
 
TPPP/p25 is primarily expressed in OLGs, where the tubulin polymerization promoting 
and MT bundling activities of the protein are crucial in the course of differentiation of the 
progenitor cells for the development of projections leading to myelination (Lehotzky et al. 2010), 
the ensheathment of the neuronal axons which facilitates the conduction of electrical impulses 
between neurons. 
 
 5.1.1. Characterization of the interaction of TPPP/p25 with tubulin/microtubules 
 
Tubulin is the main interacting partner of TPPP/p25 (Hlavanda et al. 2002); its binding 
site was predicted based on sequence homology of the TPPP/p25 and the tau protein (Hlavanda et 
al. 2007). One of the objectives of my thesis was to identify the TPPP/25 segment(s) involved in 
the binding of tubulin and MT as well as to establish the functional consequence of their hetero-
associations. 
 
Scheme 2. Various truncated forms of TPPP/p25 shown schematically. 
 
TPPP/p25 is a disordered protein with unstructured N- and C-terminal segments 
straddling a flexible, core region as suggested by PONDR predictor (Fig. 2) as well as multinuclear 
NMR studies (Zotter et al. 2011a). To characterize the role of these segments in its physiological 
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interactions, different truncated TPPP/p25 variants were produced by recombinant techniques in 
the Cell Architecture research group (Tőkési et al. 2014, Szénasi et al. 2017). The N- or C-terminal 
free as well as the double truncated (CORE) TPPP/p25 forms (shown in Scheme 2) were expressed 
in E. coli, and isolated as described in the Materials and Methods. 
The influence of the truncations of the terminal segments of TPPP/p25 on the secondary 
structure of this disordered protein was established by CD spectroscopy (Fig. 13A). The lack of 
the N- or the C-terminus resulted in minor spectral alteration, if at all; however, the double 
truncation reduced the ellipticity, characteristic to the random coil structure, indicating a less 
disordered state of the protein. 
 
Fig. 13. Normalized far-UV CD spectra (A) and the dimerization of the different TPPP/p25 forms (5 
g/lane) on non-reducing SDS-PAGE (B). FL TPPP/p25 (bold line), N TPPP/p25 (solid line), C 
TPPP/p25 (dashed line), CORE TPPP/p25 (dotted line). B. Molecular weight marker (MM). 
 
The SDS-PAGE images of the wild type and truncated forms of TPPP/p25 used for CD 
spectroscopy are shown in Fig. 13B that illustrate the presence of both monomeric and dimeric 
forms in the case of all TPPP/p25 variants, the nature of the truncations apparently do not disturb 
the monomer-dimer equilibrium of the protein. The dimers are stabilized by covalent 
intermolecular disulfide bridges by cysteine residues located in the core region of the protein (Fig. 
4). 
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5.1.1.1. TPPP/ p25 segments involved in the interaction  
 
The interaction of TPPP/p25 with tubulin results in significant secondary structural 
alteration as indicated by the difference ellipticity spectrum (Hlavanda et al. 2002). Therefore, CD 
spectroscopy was used to study the effect of the distinct segments of TPPP/p25 in its interaction 
with tubulin. As shown in Fig. 14, the difference spectrum of the tubulin-TPPP/p25 complex and 
proteins alone is reduced by removing the N-terminus that becomes more pronounced in the case 
of the C TPPP/p25 form; however, the lack of the two unstructured termini diminished the 
difference ellipticity spectrum. These data indicate that the CORE segment does not have a 
dominant role in the formation of the TPPP/p25-tubulin complex, consequently the unstructured 
termini seem to be involved in the formation of the physiological hetero-complex. 
 
 
Fig. 14. Difference ellipticity spectra of TPPP/p25 forms with tubulin. The concentration of tubulin was 1 
M, that of the TPPP/p25 forms were 4 M. Bold line: tubulin-TPPP/p25, solid line: tubulin-N 
TPPP/p25, dashed line: tubulin-C TPPP/p25, dotted line: tubulin-CORE TPPP/p25. 
 
The physiologically relevant function of TPPP/p25, namely its potency to promote the 
polymerization of tubulin into MTs, was tested by turbidity measurements. The polymerization 
was induced by the addition of the different TPPP/p25 forms. The results shown in Fig. 15 indicate 
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that the truncations depending on their nature display significant effects on the tubulin 
polymerization promoting activity:  the lack of the N- or the C-termini reduces the turbidity signals 
in a less and in a more extent, respectively, while the CORE form lost its ability to produce tubulin 
polymers. These results provide evidence for the active participation of the unstructured termini 
not only in the binding of TPPP/p25 to tubulin but in its polymerization promoting potency as 
well. In fact, electron microscopic studies in the Cell Architecture group in collaboration with the 
Department of Anatomy, Cell and Developmental Biology of ELTE revealed intact-like MT 
formation by the wild type TPPP/p25 coupled with extensive bundling activity (Hlavanda et al. 
2002); the phenomenon that the formation of the TPPP/p25-induced tubulin polymers is coupled 
with their cross-linking explains the extremely fast increase of the turbidity. 
  
 
Fig. 15. The tubulin polymerization promoting potency of the TPPP/p25 forms. The polymerizations were 
induced by stock TPPP/p25 solutions, the final concentrations were 7 M for tubulin and 3 M for the 
TPPP forms, followed by turbidimetry. 
 
The role of the truncation of TPPP/p25 in its interaction with tubulin/MT was further 
investigated by pelleting experiments. In one set of the experiments, the different TPPP/p25 forms 
were incubated with tubulin allowing them to display their potency to produce tubulin assembly, 
which was followed by separation of the polymerized and soluble tubulin by centrifugation and 
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analysis of the fractions by SDS-PAGE. As shown in Fig. 16, the FL and the N TPPP/p25 forms 
were distributed similarly in the pellet (P) and the supernatant (S) fractions, while the C and 
CORE TPPP/p25 forms appeared mostly in the supernatant indicating their poor, ability to display 
binding-induced tubulin polymerization.  
 
 
Fig. 16. The pelleting potency of the various TPPP/p25 forms. 5 M tubulin was incubated with 10 M 
TPPP/p25 forms in polymerization buffer, detected on tricine containing reducing SDS-PAGE. 
 
In another set of pelleting experiments, the effect of truncations on the bundling activity 
of TPPP/p25 was studied using paclitaxel stabilized MTs instead of tubulin. The stabilized MTs 
were incubated with the different TPPP/p25 forms and their distribution was analyzed by SDS-
PAGE. As illustrated in Fig. 17A, stabilized MTs were pelleted as expected, however, the partition 
of the TPPP/p25 forms between the pellet and supernatant fractions was dependent on the nature 
of the truncation: a part of the C and CORE TPPP/p25 remained in the soluble fraction, did not 
pelleted with the MTs, indicating their lower binding activity. In turbidity measurements, where 
tubulin was already polymerized by paclitaxel (Fig. 17B), all terminal-free forms lost their ability 
to bundle MTs (to enhance turbidity) while in similar conditions, the wild type protein produced 
fast cross-linking effect manifesting in the extensive increase of turbidity.  
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Fig. 17. The MT binding (A) and bundling (B) potency of the TPPP/p25 forms. A. The polymerization of 
10 M tubulin was induced by 20 M paclitaxel, then the MTs were bundled by 10 M TPPP forms, 
detected on SDS-PAGE. B. The polymerization of 10 M tubulin was induced by 20 M paclitaxel, then 
as indicated by an arrow, 3 M of the TPPP forms were added; followed by turbidimetry. Bold line: 
TPPP/p25, solid line: N TPPP/p25, dashed line: C TPPP/p25, dotted line: CORE TPPP/p25. 
 
The results of the binding, polymerization and pelleting experiments performed with wild 
type and truncated human recombinant TPPP/p25 variants are summarized in Table 1., which 
illustrates that the C-terminus of TPPP/p25 plays a more dominant role in the tubulin/MT binding 
and its bundling activity than its N-terminal segment. 
 
Difference in the secondary structure FL ~ ΔN ~  ΔC >> CORE 
Tubulin polymerization promoting potency FL > ΔN > ΔC >> CORE 
Binding potency of TPPP/p25 forms to tubulin FL ~ ΔN > ΔC > CORE 
MT binding potency of TPPP/p25 forms  FL ~ ΔN > ΔC > CORE 
MT bundling potency of TPPP/p25 forms FL >>ΔN ~  ΔC ~ CORE 
Table 1. Characteristics of the interactions of TPPP/p25 forms with tubulin/MT. Qualitative orders from 
left to right. 
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These in vitro data have been supported by experiments performed at cellular level with 
HeLa cells expressing TPPP/p25 ectopically. As shown in Fig. 18, the FL EGFP-TPPP/p25 co-
localizes with the MT network (Lehotzky et al. 2004), modifying the stability of the network by 
its bundling activity; these cells become more resistant against anti-mitotic agents (Lehotzky et al. 
2004). On the contrary, the EGFP-CORE TPPP/p25 does not align along the MTs, but distributed 
homogeneously within the cytosol as visualized by immunofluorescent microscopy (Tőkési et al. 
2014).  
 
 
Fig. 18. Localization of TPPP/p25 forms in HeLa cells. The expressed EGFP-TPPP/p25 (A-C, green on 
merge), EGFP-CORE TPPP/p25 (D-F, green on merge) and the MT network (A-F, red on merge) were 
visualized. Nuclei were counterstained with DAPI. Scale bar: 10 m. 
 
Similar results were obtained in living HeLa cells by bimolecular fluorescence 
complementation (BiFC) technology. In these experiments, two non-fluorescent fragments of the 
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fluorescent YFP variant mVenus (Kerppola 2008) were fused to the FL and CORE TPPP/p25 
forms. If the protein pairs attached to different mVenus fragments interact, the non-fluorescent 
fragments are brought in proximity to each other complexing into the fluorescent mVenus protein. 
Both the N- and the C-terminal Venus fragments were fused either to the FL or to the CORE 
TPPP/p25; BiFC signals were generated by co-transfection of the cells with the TPPP/p25 or 
CORE forms fused to the different mVenus BiFC constructs. As illustrated in Fig. 19, the mVenus 
BiFC signal in the case of the FL TPPP/p25 protein (A, D-F), which reflects the TPPP/p25 dimers, 
is co-localized with the MTs, FL TPPP/p25 stabilizes and bundles them; in the case of the CORE 
TPPP/p25 (B, G-I), a diffuse signal could be detected in the cytosol, independent of the MT 
network. The fact that the terminal-free form of TPPP/p25 is unable to associate with the MTs 
underlines the role of the unstructured termini in the binding to MTs in cellular environment also.  
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Fig. 19. Intracellular dimerization and localization of the TPPP/p25 and CORE pairs in HeLa cells as 
detected by BiFC assay. BiFC signals of the N- and C-segments of the Venus constructs coupled with 
TPPP/p25 (A, D-F) or CORE (CORE) TPPP/p25 pairs (B, G-I) or without them (empty Venus vectors) 
(C) as detected by immunofluorescence microscopy. BiFC signals (A-D, G) are shown as green, tubulin 
signals (E, H) are as red on merge. Nuclei were counterstained with DAPI. Scale bar: 10 m. 
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5.1.1.2. Determination of the contact surface on TPPP/p25 
 
TPPP/p25 has been reported to be a new MAP protein concerning its MT-stabilizing 
effect similarly to the tau protein (Ovádi et al. 2005). A main characteristic of these proteins is 
their unstructured feature (Goedert et al. 1991, Hlavanda et al. 2002). In addition, sequence 
homology between the tubulin binding motif of the tau protein (Kar et al. 2003) and TPPP/p25 has 
been suggested (Hlavanda et al. 2007); this segment is localized at the C-terminus of TPPP/p25 
(Fig. 20). 
 
Fig. 20. Sequence homology between the relevant MT binding regions of tau315-341 and TPPP/p25163-187. 
Created with EMBOSS Needle Pairwise Sequence Alignment 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle). 
 
To underline the predicted binding segment of TPPP/p25 involved in the tubulin binding, 
this segments was investigated experimentally using a special ELISA assay. Overlapping 
TPPP/p25 decapeptides were synthetized as dictated by the sequence homology analysis in 
collaboration with Dr. Anna Magyar of the Organic Chemistry Department of ELTE. The peptides 
were tagged on their N-termini with a cysteine residue, which made possible their direct 
immobilization to an SH-binding ELISA plate. The sequences of the decapeptides were the 
following: 
 
 P1= C163VSRLTDTTKF172 
 P2= C168DTTKFTGSHK177 
 P3= C173TGSHKERFDP182 
 P4= C178ERFDPSGKGK187 
 
The immobilized peptides were incubated with a serial dilution of tubulin, then the bound 
tubulin was quantified with a specific monoclonal tubulin antibody.  
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Fig. 21. The interaction of TPPP/p25 and the P1-P4 peptides with tubulin. TPPP/p25 (●), P1 (Δ), P2 (○), 
P3 (◊) and P4 (). 
 
As Fig. 21 shows, the P4 peptide (178-187 aa) displays comparable affinity with that of 
the wild type TPPP/p25 in tubulin binding: Kd = 0.14 ± 0.04 M for TPPP/p25 and 0.18 ± 0.03 
M for the P4 peptide; the P1, P2 and P3 peptides show significantly lower binding potency. 
Accordingly, the 178ERFDPSGKGK187 fragment within the C-terminal tail was proposed to be a 
key segment of TPPP/p25 in its tubulin binding (Tőkési et al 2014).  
 
5.1.2. Characterization of the Zn2+-induced effects on TPPP/p25 
 
The classical zinc finger motifs are considered to be consist of 2 cysteine and 2 histidine 
(C2H2) or 1 cysteine and 3 histidine (C1H3) residues centralized around a zinc ion with a short -
hairpin and a -helix structure (Gower-Winter et al. 2012). In the case of TPPP/p25, 
His61(X)10His
72(X)7Cys
80(X)2Cys
83 segment as a H2C2 zinc finger motif was identified within its 
flexible CORE region (Zotter et al. 2011b). 
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5.1.2.1. The effect of Zn2+ on the structure 
 
Previously, the Cell Architecture research group reported that the Zn2+ binding causes 
changes in the structure of TPPP/p25 as well as in its tubulin polymerization promoting activity 
(Zotter et al. 2011b). The mechanism responsible for the Zn2+-induced effects was established by 
sandwich ELISA. This specific ELISA assay renders it possible to detect only the presence of 
dimeric/oligomeric forms of a given protein (El-Agnaf et al. 2006). 
Accordingly, in this set of experiments, a monoclonal TPPP/p25 antibody was 
immobilized on the plate, TPPP/p25 with or without ZnCl2 was added in dilution series, and then 
the biotinylated form of the same monoclonal TPPP/p25 antibody was used and detected through 
peroxidase conjugated avidin reaction. This arrangement does not allow the detection of the 
monomeric TPPP/p25 species, since they have only a single epitope, thus they are unable to bind 
simultaneously to the immobilized monoclonal antibody and to the soluble one detecting the bound 
TPPP/p25. In this experimental setup, TPPP/p25 of different concentrations without or with 2 or 
10 M ZnCl2 was added to the immobilized monoclonal TPPP/p25 antibody; as a further control, 
a sample contained 10 M MnCl2 instead of the ZnCl2. In the stock solution, a significant fraction 
of TPPP/p25 is present in dimeric form (Fig. 5) which dissociates into monomers due to dilution 
if it is not stabilized by disulfide bonds (Oláh et al. 2012). The data of the sandwich ELISA 
experiment presented in Fig. 22 provided evidence for the Zn2+-enhanced dimerization. 
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Fig. 22. Effects of the bivalent Zn2+ and Mn2+ ions on the monomer-dimer equilibrium of TPPP/p25 at 
1.25 μM (black column) or 0.3125 μM (white column) protein concentration. * Significant difference, 
according to the Student's t-test, p < 0.05. 
 
The presence of Zn2+ inhibits the dissociation of the dimeric forms in the course of the 
dilution of TPPP/p25 stock solution, increasing the number of dimers present. Manganase(II) ions, 
added as MnCl2 from stock solution, has no effect on dimerization (Fig. 22). The Zn
2+-mediated 
effect at a relatively high TPPP/p25 concentration is less pronounced since the major part of the 
disordered protein is in dimeric form even in the absence of Zn2+. 
The functional consequence of the Zn2+-induced structural arrangement was analyzed by 
means of turbidity assay monitoring the tubulin assembly as illustrated on Fig. 23. Two types of 
this assay were carried out to get information on the role of Zn2+ in the dimerization of TPPP/p25: 
in one case TPPP/p25 from a stock solution was added to the tubulin diluted in the cuvette with or 
without Zn2+; in the other case the reaction was initiated by the addition of tubulin from a stock 
solution to the diluted TPPP/p25 with or without Zn2+ in the cuvette. The concentrations of tubulin, 
TPPP/p25 and ZnCl2 were identical in all turbidity assays.  
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Fig. 23. The effect of Zn2+ on tubulin polymerization. The polymerization was induced by addition of 
TPPP/p25 from a stock solution (400 M) into the diluted tubulin solution in the absence (bold line) or 
presence (dashed line) of 100 M ZnCl2; or by the addition of tubulin from the stock solution (280 M) 
into the diluted TPPP/p25 solution in the absence (solid line) and presence (dotted line) of ZnCl2. 
 
As shown in Fig. 23, the tubulin polymerization promoting potency of TPPP/p25 is 
significantly higher when the polymerization was initiated by adding a small volume from the 
stock TPPP/p25 solution as compared to that when the diluted TPPP/25 was in the cuvette and the 
reaction was started by tubulin (Oláh et al. 2012). The presence of Zn2+ apparently counteracts the 
dilution-mediated reduction of TPPP/p25 activity in both experimental setups, showing that the 
tubulin assembly mediated by the TPPP/p25 species is favored by the addition of Zn2+. The control 
experiments (without Zn2+) showed that the dimer-enriched TPPP/p25 sample (stock solution) 
displays higher polymerization activity, which can be elevated by the addition of Zn2+ in both 
cases. It should be added that without TPPP/p25, Zn2+ neither induces tubulin assembly nor 
influences the paclitaxel-induced tubulin polymerization (Zotter et al. 2011b). In summary, the 
sandwich ELISA and the turbidity measurements proved that there is a direct relationship between 
the Zn2+-induced dimerization of TPPP/p25 and its tubulin polymerization enhancing activity.   
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5.1.2.2. The effect of Zn2+ on the intracellular TPPP/p25 level 
 
The effect of Zn2+ binding to TPPP/p25 was studied at cellular level by analyzing the 
intracellular TPPP/p25 concentration in a transgenic Tet-On CHO cell line named CHO10. Since 
CHO cells do not express TPPP/p25 endogenously, the expression of this brain-specific protein 
was initiated by doxycycline (a tetracycline analogue) induction in the transgenic line. Induced 
cells were grown overnight, and then were untreated and treated with 10 M ZnCl2 for 3 hours 
(Lehotzky et al. 2015). The Zn2+ ion concentration added to the medium appears to be 
physiologically relevant, similar to that in the plasma and cerebrospinal fluid (10-20 M range in 
plasma, 2-4 µM in CSF; Mollah et al. 2008). The short time schedule of the experiment 
minimalizes the potential general protein synthesis enhancing effect of Zn2+ on transcription 
(Jackson 2008).  
The level of TPPP/p25 expression was visualized by immunofluorescence microscopy 
using mouse monoclonal TPPP/p25 antibody (Fig. 24A), and the immunopositivity was quantified 
by image densitometry of individual cells (Fig. 24B). These data revealed that Zn2+ significantly 
increased the intracellular TPPP/p25 level.  
 
 
Fig. 24. The effect of Zn2+ (10 M) on the intracellular TPPP/p25 level (red) in CHO10 cell line 
represented by immunofluorescence microscopy (A) and quantified by densitometry (B). Nuclei were 
counterstained with DAPI. Scale bar: 2.5 m. * Significant difference, according to the Student's t-test, p 
< 0.05. 
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Earlier data provided evidence for the elevation of TPPP/p25 level due to the inhibition 
of the proteasomal machinery by MG132 in HeLa cells, surmising that the intrinsically 
unstructured TPPP/p25 is degraded by the proteasome system (Lehotzky et al. 2004). It was an 
open question whether the Zn2+-induced structural changes, (the formation of the more compact 
dimers) could counteract the proteasomal degradation of the protein. To answer this, the TPPP/p25 
level was quantified by cELISA in CHO10 cells expressing TPPP/p25 treated with MG132 in the 
absence and presence of ZnCl2 (Fig. 25). The control experiment revealed that MG132 elevated 
the TPPP/p25 level due to the reduced degradation of the protein. The Zn2+ treatment produced 
similar results. The combination of the addition of MG132 and Zn2+ did not cause further 
significant elevation of the TPPP/p25 level.  
 
 
Fig. 25. Quantification of the effect of Zn2+ (10 M) on the intracellular TPPP/p25 level in CHO10 cells 
at expression levels modified with MG132 (10M). * Significant difference, according to the Student's t-
test, p < 0.05. 
 
The possibility that the addition of Zn2+ increases the synthesis of TPPP/p25, which could 
increase the TPPP/p25 level, was excluded by a similar set of experiments carried out in the 
presence of cycloheximide, a non-specific inhibitor of the protein synthesis. The treatment of the 
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cells with cycloheximide reduced the TPPP/p25 level in the control and Zn2+ supplemented 
samples; however, the addition of Zn2+ counteracted the reducing effect of cycloheximide on 
TPPP/p25 (Lehotzky et al. 2015). 
These data suggest that the Zn2+-induced structural alteration, likely the dimerization, 
protects this disordered protein against the proteolytic degradation by the proteasomal machinery. 
The proteasome system could be the main, if not exclusive, degrading system responsible for the 
elimination of the unbound TPPP/p25 (Lehotzky et al. 2004, Goldbaum et al. 2008), as described 
for many IDPs (Melo et al. 2011, Suskiewicz et al. 2011, Tsvetkov et al. 2012).  
 
5.2. Pathological interaction of TPPP/p25 with -synuclein 
 
TPPP/p25, as a NMP protein, displays not only physiological but pathological functions 
as well (Kovács et al. 2004). TPPP/p25 binds to SYN with high affinity (Oláh et al. 2011), and 
induces SYN fibrillation in vitro at substoichimetric TPPP/p25 concentration (Lindersson et al. 
2005). 
 
5.2.1. Characterization of the pathological interaction  
 
As an innovative strategy, the Cell Architecture research group aimed to identify the 
contact surface of the pathological TPPP/p25-SYN complex as a potential drug target. Targeting 
the proteins would inhibit/interfere with their physiological functions, however, targeting only 
their interface, composed of the segments of the two hallmark proteins would allow the specific 
inhibition/destruction of the TPPP/p25-SYN complex without affecting the physiological 
TPPP/p25-tubulin complex. To fulfill this task, the pathological contact segment(s) of TPPP/p25 
must be distinct from the unstructured termini that are involved in the physiological interaction 
with tubulin. 
To study the role of the unstructured N- and C-termini of TPPP/p25 in the formation of 
the TPPP/p25-SYN pathological complex, ELISA experiments were performed with FL and 
CORE TPPP/p25; TPPP/p25 forms were immobilized on the plate, SYN was added at different 
concentrations and the bound SYN was detected using a polyclonal rabbit SYN antibody.  
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Fig. 26. The binding of SYN to the FL and the CORE TPPP/p25. SYN was added at different 
concentrations to TPPP/p25 (●, , , ) or the CORE form (○, , , ). The different symbols 
indicate independent experiments. 
 
As shown in Fig. 26, SYN binds to both TPPP/p25 forms with comparable affinity, in 
agreement with the data obtained in previous Pepscan experiments (Oláh et al. 2011), suggesting 
that SYN is associated with the CORE segment of TPPP/p25. The apparent binding affinities of 
the FL and the CORE TPPP/p25 assuming simple hyperbolic saturation were comparable: 0.59 ± 
0.07 and 0.81 ± 0.09 M, respectively. 
 
5.2.1.1. Determination of the -synuclein binding site on TPPP/p25 
 
To identify the region within the CORE segment of TPPP/p25 involved in the SYN 
binding, competitive ELISA experiments with synthetized peptides were carried out. The peptides 
were designed based upon the Pepscan data (Oláh et al. 2011) that suggested the 
147KAPIISGVTKAISSPTVSRL166 segment of TPPP/p25 as a potential SYN binding domain. The 
following overlapping decapeptides with a biotin tag were synthesized by Prof. Magyar lab: 
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 BF180: C-biotinylated: Ac-142RLIEGKAPII151K-NH2 
      BF181: N-biotinylated: H-142RLIEGKAPII151 -NH2 
     BF182: C-biotinylated: Ac-147KAPIISGVTK156-NH2  
      BF183: C-biotinylated: Ac-157AISSPTVSRL166K -NH2 
 
 The biotinylated peptides were immobilized onto streptavidin covered plates, then they 
were incubated with a serial dilution of SYN and the bound SYN was quantified with a rabbit 
polyclonal SYN antibody (Fig. 27).  
 
 
Fig. 27. The interaction of TPPP/p25 fragments with SYN. BF180 (●), BF181 (○), BF182 () and 
BF183 (Δ).  
 
No significant difference was found in the binding affinity of SYN to the fragments 
immobilized on the plate (direct binding assay), in addition, the binding of SYN is apparently 
independent of the nature of the decapeptides as well as the position of the biotinylation. The 
apparent affinity constants (Kd) evaluated by fitting the saturation curves with a simple hyperbole 
were 2-4  for the BF180, BF181, BF182 and BF183 fragments. These were significantly higher 
than that determined in the case of the FL (0.59 ± 0.07 M) and the CORE (0.81 ± 0.09 M) 
TPPP/p25 meaning that the fragments display reduced affinity to SYN (Fig. 26).  
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To further analyze the interaction of these peptides with SYN, a competitive ELISA 
experiment was carried out (Fig. 28). In this setup, 10 and 20 M of the biotinylated peptides were 
premixed with SYN, then added to the plate coated with FL or CORE TPPP/p25. Therefore, the 
potential of these peptides to act as competitors of the interaction of SYN and TPPP/p25 can be 
quantified. The bound SYN was detected by polyclonal rabbit antibody. The concentration of SYN 
was constant, close to the half saturation value determined with TPPP/p25 (Fig. 26). This 
experimental setup is appropriate for screening potential drugs modifying the interaction of the 
two pathologically important proteins. 
 
 
Fig. 28. The competition of BF peptides with SYN (0.5 M) in the interaction with the TPPP forms. The 
data presented as the white column corresponds to the FL, the black one to the CORE TPPP/p25. * 
Significant difference to the control, according to the Student's t-test, p < 0.05. 
 
The fact that the binding of the FL and the CORE TPPP/p25 to SYN were similarly 
inhibited by the BF182 fragment shows its inhibition potency in the association of the two proteins 
and it is in concern with that presented above, namely, that the middle CORE region of TPPP/p25 
involves the SYN binding domain. However, the competitive ELISA data seems to contradict the 
direct binding ELISA experiments, where SYN displayed similar affinity to the biotinylated 
TPPP/p25 peptides (Kd ~ 2-4 M). A plausible explanation for this inconsistency is that the 
peptide biotinylation may play distinct roles in the direct and indirect binding experiments in the 
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interaction of TPPP/p25 with SYN. Nevertheless, ELISA data suggest that the 147KAPIISGVTK156 
segment of the CORE region is involved in the formation of the TPPP/p25-SYN complex. 
 
5.2.1.2. Determination of the TPPP/p25 binding site on -synuclein 
 
Following the interface characterization of the pathological TPPP/p25-SYN complex, I 
aimed to identify the SYN segment(s) involved in its association with TPPP/p25. Limited 
proteolytic experiments of SYN with trypsin indicated its unstructured negatively charged C-
terminal tail as a potential TPPP/p25 binding region (Szunyogh et al. 2015), therefore, recombinant 
truncated forms of SYN (Fig. 29A) were produced and used for interaction studies.  
 
Fig. 29. Recombinant mutants of SYN. A. Schematic representation of the prepared SYN forms. B. SDS-
PAGE of the SYN forms (2 g/lane) C. Selective recognition of the different antibodies against the N- 
(black column) and C-terminal (121DNEAY125, white column) of SYN. * Significant difference, according 
to the Student's t-test, p < 0.05. 
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The truncated SYN forms used for in vitro studies were as follows: SYN95-140, 
corresponding to the complete C-terminus; SYN1-120, a truncated form without the last 20 aa of the 
protein and a peptide corresponding to the last 15 aa of the C-terminus (ordered from the 
ChinaPeptides Co.). Fig. 29B shows the SDS-PAGE image of the SYN forms. The anomalously 
slow gel mobility of the relatively small SYN95-140 fragment is probably due to its low hydropathy 
(Rath et al. 2009) and its disordered state (Iakoucheva et al. 2001). Fig. 29C illustrates the 
immunopositivity of the two different antibodies with epitopes at the N- or the C-terminal SYN 
that can recognize the C- or N-truncated SYN forms, respectively. 
The interaction of the different SYN forms with TPPP/p25 was examined in two sets of 
experiments. In one set, the binding of TPPP/p25 to SYN was studied by affinity chromatography. 
SYN was bound covalently onto a CNBr-activated Sepharose 4B beads, TPPP/p25 was loaded to 
the column in the absence and presence of SYN or its truncated form, and the collected fractions 
were analysed by SDS-PAGE. The control experiment shows that the SYN affinity column is 
capable of binding TPPP/p25 according to its capacity (Fig. 30A).  
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Fig. 30. Competitive binding of TPPP/p25 to the SYN forms and the SYN affinity column. The binding 
of TPPP/p25 in the absence of further SYN forms (A), in the presence of the FL SYN (B) or SYN1-120 (C). 
 
When TPPP/p25 with excess SYN was premixed and loaded into the SYN affinity column 
(Fig. 30B), a significant fraction of the TPPP/p25 was complexed with the soluble SYN and flowed 
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through the column; thus the amount of TPPP/p25 retained by the column was significantly 
reduced compared to that when TPPP/p25 was loaded without soluble SYN (Fig. 30A). When the 
experiment was carried out with SYN1-120 (Fig. 30C), TPPP/p25 showed an elution profile identical 
to that without SYN (Fig. 30A) indicating that this long segment of SYN cannot associate with 
TPPP/p25, suggesting that the binding domain is localized on its C-terminal segment.  
The binding potencies of the FL SYN, SYN1-120 and SYN95-140 forms to TPPP/p25 were 
quantified with ELISA (Fig. 31). TPPP/p25 was added in a serial dilution to the different SYN 
forms immobilized on the plate, and the bound TPPP/p25 was detected by rat polyclonal TPPP/p25 
antibody.   
 
 
Fig. 31. The binding of TPPP/p25 to different SYN forms.  SYN (●, solid line), SYN95-140 (◊, dashed 
line), SYN1-120 (Δ, dotted line). 
 
As illustrated, TPPP/p25 showed poor binding to SYN1-120, while displayed comparable 
affinity to SYN95-140 as SYN. This finding confirms the dominant role of the 121-140 aa segment 
in the pathological complex formation. 
The contact surface of SYN involved in the TPPP/p25 binding was further investigated 
with competitive ELISA experiments. TPPP/p25 was preincubated with SYN in the presence of 
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the various SYN mutants and synthetized peptide SYN126-140, then was added to the immobilized 
SYN. The bound TPPP/p25 was detected with a rat polyclonal TPPP/p25 antibody.  
 
 
Fig. 32. The competition of the SYN forms with immobilized SYN in the binding to 125 nM TPPP/p25. 
Binding values relative to the control (no SYN) are shown. The colors indicate the presence of the 
different SYN forms: SYN (1 M) is black, SYN1-120 (1 M) is light grey, SYN95-140 (1 M) is gray and 
SYN126-140 (50 M) is dark gray; the control experiment without SYN is shown as white. * Significant 
difference, according to the Student's t-test, p < 0.05. 
 
As shown in Fig. 32, the SYN forms containing the C-terminus or its last 15 aa segment, 
but not the SYN1-120, reduced the binding of TPPP/p25 to the immobilized SYN. Therefore, it 
further reinforces that the 121-140 aa segment of SYN is involved in the formation of the 
pathological TPPP/p25-SYN complex.  
 
5.2.2. Intracellular visualization of the pathological complex        
 
TPPP/p25 is predominantly expressed in OLGs (Skjoerringe et al. 2006), while SYN is a 
neuronal protein (Iwai et al. 1995); although they are co-enriched and co-localized in both OLGs 
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and neurons of human brain in the cases of MSA and PD, respectively (Kovács et al. 2004). The 
transcellular spreading and cell-to-cell transmission of SYN has been reported (Lee et al. 2008, 
Bates et al. 2014).  
We also provided evidence for the uptake of TPPP/p25 from the medium. Its intracellular 
appearance in HeLa and CHO10 cells was detected by immunofluorescence microscopy using 
specific TPPP/p25 antibody. Both the FL and the CORE TPPP/p25 appears intracellularly, 
although the uptake of the CORE TPPP/p25 resulted in the formation of aggregates in a few cases 
(Fig. 33). 
 
 
Fig. 33. Cellular uptake of the FL (B) and the CORE TPPP/p25 (C) by immunofluorescent microscopy in 
non-induced CHO10 cells using rat polyclonal TPPP/p25 antibody. Nuclei were counterstained with 
DAPI. Scale bar: 2.5 μm. 
 
The intracellular associations of SYN with TPPP/p25 or its CORE (SYN binding) form 
were characterized in the CHO10 cell line. After premixing SYN with either the FL or the CORE 
TPPP/p25 forms, the proteins were added to the medium to be taken up by the cells. Following 
incubation, the cells were fixed and the localization and enrichment of both TPPP/p25 forms and 
SYN were detected by immunocytochemistry.  
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Fig. 34. Intracellular aggregation of the FL or CORE TPPP/p25 (2.5 M) with or without SYN (10 M), 
the proteins were premixed and added to the medium of CHO10 cells as indicated. Nuclei were 
counterstained with DAPI. Scale bar: 2.5 m. 
 
As shown in Fig. 34, the CORE form resulted in more extensive aggregation than the 
recombinant FL TPPP/p25 due to the fact that the termini-free CORE TPPP/p25 is unable to bind 
to the MT network (Fig. 9Fig. 18). These findings not only provide evidence that TPPP/p25 and 
SYN associates intracellularly, but also highlight, in agreement with the in vitro data, that the 
CORE segment of TPPP/p25 is involved in the formation of their pathological aggregation. 
To validate the role of the SYN126-140 segment of the C-terminus in the co-aggregation of 
TPPP/p25 and SYN, a similar set of experiments was carried out with CHO10 cells in the presence 
of the SYN126-140 fragment as a potential binding partner of TPPP/p25. In this type of experiment, 
concentrations of CORE TPPP/p25 and SYN were slightly higher in order to promote the 
aggregation of the proteins, to visualize the effectivity of the SYN fragment. 
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Fig. 35. Intracellular aggregation as a result of the association of the different TPPP/p25 (3 M) and SYN  
forms (12 M). The FL (A, C, E, globally the left side) or CORE (D, F) TPPP/p25 and/or SYN (B, C, D), 
and FITC-SYN126-140 (E, F) were premixed then added to the medium of the cells. The exposure times 
were 1 s, except in panel D, where it had been reduced to 0.1 s, due to the high fluorescent intensity of the 
co-aggregates of the CORE TPPP/p25 and SYN (merge). Nuclei were counterstained with DAPI. Scale 
bar: 5 μm. 
 
The results obtained with TPPP/p25 and SYN forms expected to be involved in the 
formation of their pathological complex can be visualized in Fig. 35. As shown in Fig. 35A and 
B, the cells treated with FL TPPP/p25 or SYN showed virtually no aggregations. The premixing 
of TPPP/p25 with the FL or the FITC labelled SYN126-140 (Fig. 35C and E) resulted in small 
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intracellular co-aggregates. In the case of SYN1-120 premixed with TPPP/p25, no aggregation was 
observed (detected with the rabbit monoclonal SYN antibody specific for the N-terminus of SYN, 
data not shown). The CORE TPPP/p25 premixed with the FL SYN (Fig. 35D) produced intensive 
aggregation indicating their massive aggregation-prone potency. The co-enrichment of the CORE 
TPPP/p25 with the SYN126-140 (Fig. 35F) peptide underlines their role in the constitution of the 
contact surface of the pathological complex, as well as validates the segments of the CORE 
TPPP/p25 and the very last aa of the C-terminus of SYN as contact surface of the pathological 
complex.  
 
5.2.3. Impact of the presented data in Parkinson research  
 
Currently there is no cure for PD, but medications can help to control its symptoms, which 
are caused by the death of dopaminergic neurons, thus the lack of dopamine in the brain (Chinta 
et al. 2005, Surmeier et al. 2010). Many anti-Parkinson drugs aim either temporarily replenish 
dopamine or mimic the action of dopamine (levodopa, dopamine agonists; Jankovic et al. 2008). 
However, current therapies are only symptomatic treatments. The mechanisms which lead to 
inclusion formation and later the loss of dopaminergic neurons are still under intense investigation. 
The results presented in my PhD dissertation could open a door to a new, innovative 
strategy in Parkinson research: the validation of a novel drug target for PD, which is a key issue. 
Nowadays, it is clear that SYN and its interacting partner, TPPP/p25 are hallmarks of PD and other 
synucleinopathies, yet targeting these multifunctional hallmarks themselves cannot provide 
appropriate therapeutic solution probably since both proteins are involved in physiological and 
pathological events. In order to destruct the pathological complex without affecting the 
physiological one, the interface of the pathological TPPP/p25-SYN complex was considered to be 
a potential drug target. This task could be successful if the contact surface of the pathological 
complex is distinct from that of the physiological one. The presented data suggest that the 
segment(s) of TPPP/p25 involved in SYN binding is localized within the flexible, middle CORE 
region, while the segment associates with tubulin can be found dominantly in its unstructured C-
terminus. Therefore, there is an opportunity to develop powerful specific anti-Parkinson agents 
with limited toxic side effects. 
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The Cell Architecture research group have developed a specific competitive ELISA assay 
for the in vitro screening of compounds that inhibit/destruct the TPPP/p25-SYN complex but not 
the TPPP/p25-tubulin interaction. With this method, the effectivity of the inhibitors could be 
quantified as well.  This test could be a first step in the validation of a potential drug; it renders the 
evaluation of peptides or peptide derivatives possible leading to the construction of 
peptidomimetic foldamers. Furthermore, we have established a CHO10 cell model suitable to 
detect TPPP/p25-SYN aggregates, which gives rise to the possibility to test any promising 
compounds/fragments also in cell cultures for their potential activity to inhibit or reduce the 
formation of these pathological aggregates. 
The recognition that both SYN and TPPP/p25 can be transferred from the medium into 
the cells suggests their potency to be transported from extracellular space. This issue largely 
contributes to our understanding how these proteins can co-enrich and co-localize in inclusion 
bodies characteristic not only in PD but also in MSA, despite the fact that they are expressed in 
distinct cell types in normal brain. The occurrence of SYN and TPPP/p25 was detected in 
cerebrospinal fluid samples of human patients previously (Borghi et al. 2000, Vincze et al. 2011, 
Marques et al. 2012), which supports this assumption as well.   
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6. SUMMARY 
The brain-specific Tubulin Polymerization Promoting Protein (TPPP/p25) as a 
Microtubule Associated Protein is an intrinsically disordered protein that primarily is expressed in 
oligodendrocytes and plays a crucial role in the differentiation of progenitor cells at physiological 
circumstances; however, its co-enrichment and co-localization with -synuclein (SYN) occur at 
pathological condition leading to the etiology of synucleinopathies. Within the frame of my PhD, 
I aimed to characterize the homo-and hetero-associations of TPPP/p25 and their functional 
consequences. Experiments with the human recombinant wild type and the truncated variants of 
TPPP/p25 provided evidence for the ability and significance of dimerization of the unfolded 
monomeric TPPP/p25 that has a determining role in the microtubule assembly, as well as in the 
interaction with tubulin and microtubules as physiological partners. The Zn2+, as a specific bivalent 
cation, causes dimerization with a more compact structure. The relevance of the dimeric form was 
demonstrated in HeLa cells with bimolecular fluorescent microscopy. The Zn2+ bound TPPP/p25 
is more resistant to proteolytic digestion, therefore Zn2+ seems to be involved in the fine-tuning of 
the physiological TPPP/p25 level. The protein is a prototype of the Neomorphic Moonlighting 
Proteins, possesses both physiological and pathological functions. The pathological partner is the 
disordered SYN, hallmark of the Parkinson’s disease and other synucleinopathies. Since both 
proteins play important physiological roles, they cannot be specific drug targets by themselves. 
The innovative strategy of the Cell Architecture research group is to target the interface of the 
pathological TPPP/p25-SYN complex without affecting the physiological interactions. The 
interfaces of the pathological TPPP/p25-SYN and the physiological TPPP/p25-tubulin complex 
were identified with truncated protein forms and peptides by circular dichroism, ELISA, 
turbidimetry and affinity chromatography. Distinct segments of TPPP/p25 are involved in the 
different complexes: tubulin interacts primarily with the unstructured C-terminus of TPPP/p25; 
while the C-terminus of the SYN associates with the flexible CORE segment of TPPP/p25. This 
situation renders it possible to design selective anti-Parkinson drugs.  In addition, the results 
presented in this thesis introduce an in vitro method (competitive ELISA), which is appropriate 
for screening potential drugs, and a cell model, which is capable of TPPP/p25 and SYN uptake 
and the two hallmark proteins and their relevant fragments form intracellular aggregates, thus this 
cell model provides the opportunity to visualize the inhibitory effect of the drugs, selected on the 
basis of in vitro data, by fluorescence microscopy and also to quantify it by Western blot. 
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7. ÖSSZEFOGLALÁS 
Az eredendően rendezetlen, agyspecifikus „Tubulin Polymerization Promoting Protein” (TPPP/p25) 
elsődlegesen az oligodendrocitákban fejeződik ki és fiziológiás körülmények között, mint 
mikrotubulus asszociált fehérje a progenitor sejtek differenciációjában játszik létfontosságú szerepet. 
Patológiás körülmények között azonban az -synucleinnel (SYN) együtt halmozódik fel, 
hozzájárulva ezzel a szinukleinopátiás betegségek kialakulásához. PhD tanulmányaim keretein belül 
célom volt a TPPP/p25 homo- és hetero-asszociációinak vizsgálata és azok funkcionális 
következményeinek megismerése. A csonkolt és vad típusú TPPP/p25-tel végzett kísérletek 
bizonyították a fehérje dimerizációs képességét és annak meghatározó szerepét a 
tubulinnal/mikrotubulussal való kölcsönhatásban és az általa indukált mikrotubulusok 
kialakulásában. A cink kation a fehérje dimerizációját indukálja, elősegítve ezzel a rendezetlen 
monomereknél kompaktabb, dimer struktúra kialakulását. A TPPP/p25 dimer formájának 
relevanciáját HeLa sejtben bimolekuláris fluoreszcencia komplementációval bizonyítottam. A cink-
indukált TPPP/p25 formák ellenállóvá válnak a proteolitikus emésztéssel szemben, ami hozzájárulhat 
a fiziológiás TPPP/p25 szint finomhangolásához. E fehérje a „Neomorphic Moonlighting” Fehérjék 
prototípusaként fiziológiás és patológiás funkciókkal is rendelkezik, patológiás partnere a SYN, a 
Parkinson-kór és más szinukleinopátiák marker fehérjéje. Mivel mindkét fehérje fontos fiziológiás 
funkcióval bír, így specifikus gyógyszercélpontként önmagukban nem támadhatók. A 
Sejtarchitektúra kutatócsoport innovatív stratégiája szerint a patológiás TPPP/p25-SYN komplex 
kötőfelszínét kell megcélozni, hogy a fiziológiás funkció ne változzon. A patológiás TPPP/p25-SYN 
és a fiziológiás TPPP/p25-tubulin komplex felületét in vitro kísérletekben csonkolt fehérje formák és 
peptidek segítségével cirkuláris dikroizmus, ELISA, turbidimetriás és affinitás kromatográfiás 
mérésekkel azonosítottam. Eltérő szegmensek vesznek részt a komplexek kialakításában: elsősorban 
a TPPP/p25 rendezetlen C-terminálisa kötődik a tubulinhoz, a SYN C-terminálisa viszont a TPPP/p25 
flexibilis CORE régiójával hat kölcsön. Az eltérő kötőhelyek lehetővé teszik szelektív Parkinson-kór 
elleni gyógyszerek kifejlesztését. Ezen kívül a leírt eredmények között bemutatok egy in vitro 
módszert (kompetitív ELISA), amely alkalmas lehetséges gyógyszerek „screen”-elésére; továbbá egy 
sejtmodellt, amely a TPPP/p25-öt és a SYN-t képes felvenni a médiumból, és e két „hallmark” fehérje 
valamint azok releváns fragmensei intracelluláris aggregátumokat képeznek. Így a sejtmodell 
lehetőséget nyújt arra, hogy az in vitro adatok alapján kiválasztott gyógyszerek gátló képességeit 
fluoreszcencia mikroszkópiával vizsgáljuk és Western-blottal kvantifikáljuk. 
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